



# Glycosyltransferase POMGNT1 deficiency strengthens N-cadherin-mediated cell–cell adhesion

Received for publication, September 9, 2020, and in revised form, February 8, 2021. Published, Papers in Press, February 18, 2021, <https://doi.org/10.1016/j.jbc.2021.100433>

Sina Ibne Noor<sup>1</sup>, Marcus Hoffmann<sup>2</sup>, Natalie Rinis<sup>1</sup>, Markus F. Bartels<sup>1</sup>, Patrick R. Winterhalter<sup>1</sup>, Christina Hoelscher<sup>1</sup>, René Hennig<sup>2,3</sup>, Nastassja Himmelreich<sup>4</sup>, Christian Thiel<sup>4</sup>, Thomas Ruppert<sup>5</sup>, Erdmann Rapp<sup>2,3</sup>, and Sabine Strahl<sup>1,\*</sup>

From the <sup>1</sup>Centre for Organismal Studies (COS), Glycobiology, Heidelberg University, Heidelberg, Germany; <sup>2</sup>Max Planck Institute for Dynamics of Complex Technical Systems, Bioprocess Engineering, Magdeburg, Germany; <sup>3</sup>glyXera GmbH, Magdeburg, Germany; <sup>4</sup>Center for Child and Adolescent Medicine, Department Pediatrics I, University of Heidelberg, Heidelberg, Germany; and <sup>5</sup>Center for Molecular Biology of Heidelberg University (ZMBH), DKFZ-ZMBH Alliance, Heidelberg, Germany

Edited by Gerald Hart

Defects in protein *O*-mannosylation lead to severe congenital muscular dystrophies collectively known as  $\alpha$ -dystroglycanopathy. A hallmark of these diseases is the loss of the *O*-mannose-bound matriglycan on  $\alpha$ -dystroglycan, which reduces cell adhesion to the extracellular matrix. Mutations in protein *O*-mannose  $\beta$ 1,2-*N*-acetylglucosaminyltransferase 1 (POMGNT1), which is crucial for the elongation of *O*-mannosyl glycans, have mainly been associated with muscle–eye–brain (MEB) disease. In addition to defects in cell–extracellular matrix adhesion, aberrant cell–cell adhesion has occasionally been observed in response to defects in POMGNT1. However, specific molecular consequences of POMGNT1 deficiency on cell–cell adhesion are largely unknown. We used *POMGNT1* knockout HEK293T cells and fibroblasts from an MEB patient to gain deeper insight into the molecular changes in POMGNT1 deficiency. Biochemical and molecular biological techniques combined with proteomics, glycoproteomics, and glycomics revealed that a lack of POMGNT1 activity strengthens cell–cell adhesion. We demonstrate that the altered intrinsic adhesion properties are due to an increased abundance of N-cadherin (N-Cdh). In addition, site-specific changes in the *N*-glycan structures in the extracellular domain of N-Cdh were detected, which positively impact on homotypic interactions. Moreover, in POMGNT1-deficient cells, ERK1/2 and p38 signaling pathways are activated and transcriptional changes that are comparable with the epithelial–mesenchymal transition (EMT) are triggered, defining a possible molecular mechanism underlying the observed phenotype. Our study indicates that changes in cadherin-mediated cell–cell adhesion and other EMT-related processes may contribute to the complex clinical symptoms of MEB or  $\alpha$ -dystroglycanopathy in general and suggests that the impact of changes in *O*-mannosylation on *N*-glycosylation has been underestimated.

The modification of proteins by glycosylation is a ubiquitous feature of all living organisms (1). Protein-linked glycans are involved in a multitude of cellular processes ranging from monitoring the folding state of glycoproteins to cell adhesion and migration (2). Among the different types of glycosylation, *N*-glycosylation and *O*-mannosylation are evolutionary conserved from bacteria to mammals. In humans, changes in those essential protein modifications *inter alia* can modulate immune responses, promote cancer cell metastasis, and underlie the pathophysiology of severe congenital disorders (3–5). Both modifications initiate at the endoplasmic reticulum (ER), where the target polypeptides and the donor saccharides are synthesized and eventually covalently linked (2). Only properly glycosylated and folded proteins can leave the ER and travel through the Golgi apparatus to reach their final cellular destinations. On their way, *N*-linked and *O*-mannosyl glycans can be further modified, which leads to diverse species- or even cell-type-specific glycans (2).

In the case of *N*-glycosylation, the dolichol-pyrophosphate-linked oligosaccharide Glc<sub>3</sub>Man<sub>9</sub>GlcNAc<sub>2</sub> is assembled at the ER membrane and the glycan moiety is transferred *en bloc* to Asn residues of the consensus sequon Asn-X-Ser/Thr/Cys (X: proline is excluded). This way, the vast majority of proteins that enter the secretory pathway are *N*-glycosylated including many cell surface receptors and cell adhesion molecules (6). Protein-linked carbohydrate moieties are then further processed and finally extended in the Golgi through the concerted action of diverse specific glycosyltransferases resulting in three distinct types of *N*-glycans: high-mannose, complex-, and hybrid-type, which contain the common core Man<sub>3</sub>GlcNAc<sub>2</sub>-Asn (2). The diverse glycan structures and glycosylation patterns on cell surface molecules are highly dynamic and can be differentially regulated both during development and in certain pathological conditions, often associated with the acquisition of altered cellular properties (4).

Classically, *O*-mannosylation is initiated by the conserved PMT family of protein *O*-mannosyltransferases (POMT1 and POMT2 in mammals), which catalyze the transfer of mannose from dolichol-phosphate-linked mannose to Ser and Thr

\* For correspondence: Sabine Strahl, [sabine.strahl@cos.uni-heidelberg.de](mailto:sabine.strahl@cos.uni-heidelberg.de). Present address for Patrick R. Winterhalter: Clinic for Heart Surgery, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.

## POMGNT1 impacts on N-cadherin-mediated cell–cell adhesion

residues of nascent proteins (7). Three different core structures can be built on the protein-linked mannose (8). Linear core m1 and branched core m2 glycans, which share the common inner core GlcNAc- $\beta$ 1,2-Man-Ser/Thr, are initiated in the cis Golgi by the addition of a GlcNAc residue by the protein *O*-mannose  $\beta$ 1,2-*N*-acetylglucosaminyltransferase 1 (POMGNT1), and are further extended while proteins travel through the Golgi to the cell surface. In contrast, core m3 glycans are already elongated in the ER (GalNAc- $\beta$ 1,3-GlcNAc- $\beta$ 1,4-(phosphate-6)-Man-Ser/Thr) and then further modified in the Golgi by the sequential action of numerous glycosyltransferases including the ribulose-5-phosphate transferase fukutin (FKTN). The resulting complex polysaccharide structure, known as “matriglycan,” is so far only found on  $\alpha$ -dystroglycan ( $\alpha$ -DG), a central member of the dystrophin glycoprotein complex family in peripheral membranes and enables its interaction with extracellular matrix (ECM) components such as laminin (9). Defects in this complex biosynthetic pathway lead to the loss of the matriglycan on  $\alpha$ -DG and consequently impair interactions between  $\alpha$ -DG and, e.g., laminin, which interferes with the formation of basement membranes (9). This defect has been recognized as a major patho-mechanism of severe congenital muscular dystrophies with neuronal migration defects, known as  $\alpha$ -dystroglycanopathy (OMIM 236670; 253280; 253800; 606612; 607155; 608840) (10).

The glycosyltransferase POMGNT1 has a key role in the elongation of *O*-mannosyl glycans (11). In its absence, not only core m1 and m2 structures are missing, also formation of the matriglycan fails, since POMGNT1 recruits FKTN to maturing core m3 structures (12, 13). The great majority of mutations in *POMGNT1* have been linked to muscle–eye–brain disease (MEB; OMIM 253280), a congenital muscular dystrophy in humans, which is characterized by additional brain malformations and structural anomalies in the eye (11). In the murine model, knockout of *POMGNT1* is viable with multiple developmental defects, similar to the clinical picture of human MEB patients (14, 15). The pathology of MEB suggests a functional role for POMGNT1 in control of cell adhesion and migration. For example, in the transgenic *POMGNT1*-based MEB mouse model, impaired cell–ECM adhesion results in disruption of basement membranes and overmigration of neurons during development of the cerebral cortex (15). However, also clusters of granule cells, which failed to migrate, have been frequently observed (15). In addition to its important role during mammalian development, POMGNT1 has recently been linked to the progression of glioblastoma, fatal primary brain tumors with survival time of 12–15 months, as well as the resistance of glioblastoma cells to the chemotherapeutic agent temozolomide (16, 17). Strikingly, in glioblastoma models, increased cell–cell adhesion has been observed when POMGNT1 is missing (16). However, molecular reasons for the different consequences of POMGNT1 deficiency are just emerging.

Very recently, glyco-engineered human embryonic kidney (HEK) 293 cells turned out to be especially useful for the characterization of known, as well as the identification of new glycosylation pathways (18, 19). In the present work, we took

advantage of a gene-targeted *POMGNT1* knockout in HEK293T cells to study the consequences of POMGNT1 deficiency. The combination of glyco(proteo)omics with classic biochemistry, molecular and cell biology resulted in the discovery that cell–cell adhesion mediated by neuronal cadherin (N-Cdh) is affected and defined a possible molecular mechanism underlying the observed phenotype. Similar effects in MEB patient-derived fibroblasts confirmed the validity of the HEK293T model to study molecular effects of *O*-mannosylation deficiencies.

## Results

### *POMGNT1* deficiency impairs cell–matrix and reinforces cell–cell interactions in a HEK293T cell model


To gain insight into functional implications of POMGNT1 deficiency, we generated a gene-targeted knockout in HEK293T cells ( $\Delta$ POMGnT1) as detailed in Experimental procedures and Figure S1. The loss of POMGNT1 activity was confirmed by the *O*-mannosylation status of the endogenous substrate  $\alpha$ -DG using the matriglycan-directed antibody IIH6. Whereas the *O*-linked matriglycan is absent in POMGNT1-depleted cells, reintroduction of human *POMGNT1* rescued *O*-mannosylation of  $\alpha$ -DG verifying the specificity of the system (Fig. 1A). General characterization of the morphology of *POMGNT1* knockout cells by confocal microscopy revealed that POMGNT1-deficient cells appear more rounded and stronger aggregated compared with wild-type (WT) cells, which show extensive spreading and even distribution. This phenotype is also reverted upon reintroduction of *POMGNT1* (Fig. 1B).

To further characterize molecular events responsible for the morphological differences, we analyzed cell–matrix and cell–cell adhesion. As expected, POMGNT1-deficient cells adhere to laminin, a major ECM component and interactor of the  $\alpha$ -DG matriglycan, to a significantly lower extent when compared with WT cells (Fig. 2A). Intriguingly, when confluent monolayers of WT cells were incubated with WT and knockout cells, respectively, cell–cell adhesion of  $\Delta$ POMGnT1 cells turned out to be significantly increased. The same result is observed using a monolayer of  $\Delta$ POMGnT1 cells (Fig. 2B). Since cell–matrix and cell–cell interactions are major opposing forces balancing cellular migration, we further took advantage of xCELLigence real-time cell analysis that allows live monitoring of cell proliferation and cell migration.  $\Delta$ POMGnT1 cells proliferate slower than WT cells with slopes of 0.07 and 0.09, respectively (Fig. S2, A and B). In agreement with increased cell–cell adhesion, the migration rate of  $\Delta$ POMGnT1 cells is reduced by a factor of 3 (Figs. 2C and S2D).

Taken together, the *POMGNT1* knockout HEK293T cell model revealed that cell–cell adhesion increases, whereas cell–matrix interactions and cell migration are negatively affected when *O*-mannosyl glycans are not further elongated.

### Increased cell–cell adhesion of *POMGNT1*-deficient cells is mediated by N-Cdh


In order to identify determinants that underlie the observed phenotype in  $\Delta$ POMGnT1 cells, we performed label-free



**Figure 1. Characterization of *POMGNT1* knockout HEK293T cells.** *A, B*, WT and  $\Delta$ POMGnT1 cells with or without *POMGNT1* complementation are shown.  $\Delta$ POMGnT1 cells were stably transfected with either empty vector ( $\Delta$ POMGnT1 + empty vector) or vector carrying *POMGNT1* ( $\Delta$ POMGnT1 + *POMGNT1*). *A*, western blot analysis of  $\alpha$ -DG from wheat germ agglutinin-enriched fractions (*first and second panel*). Genome targeting of *POMGNT1* results in loss of its enzymatic activity as demonstrated by the lack of matriglycan on  $\alpha$ -DG (as identified by IIH6 immuno-reactivity) (compare lanes 1 and 2). *O*-mannosylation of  $\alpha$ -DG is restored upon reintroduction of *POMGNT1* (compare lanes 2 and 4). Analysis of whole-cell lysates with anti-5x-His antibody shows His-tagged *POMGNT1* in  $\Delta$ POMGnT1 cells (third and fourth panel).  $\beta$ -DG served as a loading control for the wheat germ agglutinin-enriched fractions and  $\alpha$ -Tubulin ( $\alpha$ -Tub) for the whole-cell lysates. *B*, confocal images displaying differences in cell-cell adhesion among WT,  $\Delta$ POMGnT1, and *POMGNT1*-transfected  $\Delta$ POMGnT1 cells. In the *upper panels*, cells fixed and stained with Rhodamine Phalloidin (*red*; actin filaments) and DAPI (*blue*; nucleus) after 3 days of seeding are shown (scale bar: 10  $\mu$ m). In the *lower panels*, the area of interest of each image is magnified (scale bar: 5  $\mu$ m).


quantitative proteomics of whole-cell lysates from WT and  $\Delta$ POMGnT1 HEK293T cells. Five independent replicates were analyzed, and homoscedasticity and normal distribution were confirmed (Fig. S3, *A* and *B*, Tables S1–S3). Altogether, 86 out of 437 proteins with differential abundance in *POMGNT1*-deficient cells could be identified (Fig. 3*A* and S3*D*, Table S4). Interestingly, gene ontology term functional annotation of proteins with a significant regulation revealed enrichment for proteins under the molecular function term of

"cadherin binding involved in cell-cell adhesion" (Figs. 3*A* and S3*D*, Table S4), pointing to an impact of *POMGNT1* deficiency on cadherin-mediated cell-cell adhesion. In addition, the protein N-Cdh was found to be more abundant by a factor of  $\sim 2.7$  in  $\Delta$ POMGnT1 cells (Fig. 3*A*). This result was also confirmed by western blot (Fig. 3, *B* and *C*) and correlated well with increased mRNA levels of N-Cdh (Fig. 3*D*). The observed difference in the increase of N-Cdh abundance in proteomics ( $\sim 2.7$ -fold) and western blot analysis ( $\sim 1.4$ -fold) is most likely



**Figure 2. *POMGNT1* deficiency affects cell adhesion and migration in HEK293T cells.** *A*, relative adhesion of WT and  $\Delta$ POMGnT1 cells to the ECM component laminin. WT or  $\Delta$ POMGnT1 cells deprived of FBS were seeded on laminin or BSA (as a control) precoated wells and allowed to adhere for 1 h at 37 °C. Adherent cells were stained with crystal violet and quantified at OD<sub>600</sub> after stain extraction. The absorbance for each laminin-coated well was normalized against the mean absorbance of BSA-coated wells. Adhesion of  $\Delta$ POMGnT1 cells to laminin is represented as relative adhesion in %, considering adhesion of WT cells to laminin as 100%. *B*, relative cell-cell adhesion of WT and  $\Delta$ POMGnT1 cells to cell monolayers as indicated. WT or  $\Delta$ POMGnT1 cells deprived of FBS were seeded on confluent monolayers of cells with either the same or different genotype and allowed to adhere for 20 min at 37 °C. Adherent cells were stained with crystal violet and quantified at OD<sub>600</sub> after stain extraction. The absorbance of each well to which cells were added was normalized against the mean absorbance of wells, where no cells were added. Respective cell-cell adhesion is represented as relative adhesion in %, considering adhesion of WT to WT cells as 100%. *C*, comparison of the migration rate between WT and  $\Delta$ POMGnT1 cells. WT and  $\Delta$ POMGnT1 cells deprived of FBS were seeded on xCELLigence microelectrode-equipped trans-well chambers and allowed to migrate for 90 h at 37 °C. Migration was monitored in real time as increase of impedance and was expressed as Cell Index, an arbitrary unit. The migration rate was calculated from the slope of the curves between 20 h and 60 h (Fig. S2*D*). *A–C*, assays were performed at least in triplicate from two independent experiments. Data are represented as means  $\pm$  SD including all individual data points. Asterisks denote statistical significance in comparison with WT cells: \*\*\**p*  $\leq$  0.001. FBS, fetal bovine serum.

## POMGNT1 impacts on N-cadherin-mediated cell–cell adhesion



**Figure 3. Defects in *POMGNT1* induce expression of N-Cadherin.** *A*, volcano plot of differentially expressed proteins of WT and  $\Delta$ POMGNT1 cells identified by label-free LC-MS/MS of five biological replicates each. The solid lines represent the threshold of statistical significance with false discovery rate (FDR) < 0.05 and an  $s_0$  of 0.1 (controlling the relative importance of *t*-test *p*-value and the difference between means). The complete list of proteins is included in Table S4. Proteins with a significant fold change are depicted in blue dots, with a subset of cadherin-associated proteins in red dots. Gray dots indicate proteins that failed to meet the criteria of FDR or fold change. *B*, *E*, representative western blot used for N-Cdh protein quantification in membrane fractions (corresponding to 20  $\mu$ g of total membrane protein) from WT and  $\Delta$ POMGNT1 cells (*B*) and from control and MEB patient-derived fibroblasts (*E*). Sec61 $\alpha$  was used as loading control. *C*, *F*, densitometry-based quantification of N-Cdh signal detected by western blot in WT and  $\Delta$ POMGNT1 cells (*C*) and in control and MEB patient-derived fibroblasts (*F*). N-Cdh signals for  $\Delta$ POMGNT1 cells and MEB patient-derived fibroblasts were normalized to the respective Sec61 $\alpha$  signal and subsequently normalized to the N-Cdh/Sec61 $\alpha$  ratio calculated for WT cells and control fibroblasts, respectively. Protein levels of N-Cdh are represented in %, considering pixel density of N-Cdh in WT cells and control fibroblasts as 100%, respectively. Assays were performed with three biological replicates. *D*, *G*, qRT-PCR analysis of *CDH2* mRNA levels in WT and  $\Delta$ POMGNT1 cells (*D*) and in control and MEB patient-derived fibroblasts (*G*). *CDH2* mRNA levels in  $\Delta$ POMGNT1 cells and MEB patient-derived fibroblasts are calculated as %, considering *CDH2* mRNA levels in WT cells and control fibroblasts as 100%, respectively. For normalization the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase was used. Assays were performed in duplicate from three biological replicates. Data are represented as means  $\pm$  SD including all individual data points. Asterisks denote statistical significance in comparison with WT cells: \*\*  $p \leq 0.01$ , \*\*\*  $p \leq 0.001$ .


due to the different detection principles that could be influenced by changes in N-Cdh glycosylation (see below).

To investigate the general validity of our findings, we took advantage of skin fibroblasts derived from an MEB patient who presented characteristic symptoms such as mental retardation and blindness due to variant c.535\_751del (p.Asp179Argfs\*11) in the *POMGNT1* gene (NM\_017739.4). In accordance with our HEK293T model, protein and mRNA abundance of N-Cdh in MEB patient-derived fibroblasts showed increased values compared with fibroblasts from two healthy donors (Fig. 3, E–G).

Cadherins are major players in the formation of cellular junctions (20). These membrane-anchored cell surface glycoproteins mediate cell–cell adhesion through homotypic interactions of their conserved extracellular domains. Thus, to determine whether elevated cell–cell adhesion observed in *POMGNT1*-deficient cells is directly linked to the increased abundance of N-Cdh, we performed cell–cell adhesion assays in presence of either N-Cdh blocking or IgG-directed antibodies. As shown in Figure 4,  $\Delta$ POMGNT1 cells show increased adhesion to WT and other  $\Delta$ POMGNT1 cells in the IgG-treated controls. This increase, however, is diminished upon incubation with an N-Cdh targeting antibody, demonstrating N-Cdh as a key molecular driver for increased cell–cell adhesion in the established  $\Delta$ POMGNT1 HEK293T cell model.

### *POMGNT1* deficiency affects N-Cdh N-glycosylation

N-Cdh is highly N-glycosylated and N-linked glycans affect its adhesive properties by modulating its homomeric interactions in cis and in trans (21, 22). We therefore asked whether an altered N-glycosylation, as an indirect effect of *POMGNT1* deficiency, could contribute to increased N-Cdh-mediated cell–cell adhesion. We performed comprehensive N-glycomics and N-glycoproteomics on N-Cdh. For that purpose, the extracellular domain (EC) of N-Cdh was recombinantly expressed and purified from WT and  $\Delta$ POMGNT1 cells (detailed in Experimental procedures; Fig. S4). N-glycomics analysis by multiplexed capillary gel electrophoresis with laser-induced fluorescence detection (xCGE-LIF) revealed that total abundance of fully galactosylated and sialylated ( $\alpha$ 2,6- and  $\alpha$ 2,3-NeuNAc) N-glycan structures is remarkably decreased on N-Cdh derived from  $\Delta$ POMGNT1 cells when compared with WT (Fig. 5A, normalized intensity of peaks 2, 4, 9, and 10; Fig. S5 and Table S5). In accordance, the abundance of non-galactosylated N-glycan structures is increased (Fig. 5A, normalized intensity of peaks 6 and 7). Moreover, fully galactosylated multiantennary N-glycans (Fig. 5A, normalized intensity of peak A3+F) are reduced on  $\Delta$ POMGNT1-derived N-Cdh, and a nongalactosylated complex-type N-glycan with a bisecting GlcNAc (GlcNAc(5)Man(3)+Fuc(1)) represents the dominating N-glycan structure.



**Figure 4. Increased cell-cell adhesion of POMGNT1-deficient cells is mediated by increased abundance of N-cadherin.** Relative cell-cell adhesion of WT (bright bars) and ΔPOMGnT1 (dark bars) cells to the indicated cell monolayers in the presence of either N-Cdh targeting or anti-human IgG antibody. WT or ΔPOMGnT1 cells that were deprived of fetal bovine serum, were incubated with an anti-N-Cdh antibody, and subsequently seeded on an anti-N-Cdh antibody-treated confluent monolayer of cells. Anti-human IgG antibody served as a control. Cells were allowed to adhere for 20 min at 37 °C. Adherent cells were stained with crystal violet and quantified at OD<sub>600</sub> after stain extraction. The absorbance of each well to which cells were added was normalized against the mean absorbance of wells, where no cells were added. Respective cell-cell adhesion is represented as relative adhesion in %, considering relative adhesion of WT to WT cells pretreated with anti-human IgG antibody as 100%. Assays were performed in triplicate from two independent experiments. Data are represented as means ± SD including all individual data points. Asterisks denote statistical significance in comparison with WT cells: \**p* ≤ 0.05, \*\*\**p* ≤ 0.001. n.s., not significant.

In order to gain even deeper insights, an exploratory site-specific approach was taken to comprehensively map glycosylation sites and the corresponding *N*-glycoforms of N-Cdh. Hydrophilic interaction liquid chromatography (HILIC)-enriched tryptic and proteinase K-generated N-Cdh *N*-glycopeptides were analyzed by nano-reverse-phase liquid chromatography coupled online to an electrospray ionization orbitrap tandem mass spectrometer (nano-RP-LC-ESI-OT MS/MS) (for details see Experimental procedures). All eight potential *N*-glycosylation sites (Asn190, 273, 325, 402, 572, 622, 651, 692) of N-Cdh were identified (Fig. 5B, indicated as red ribbons, and Table S6). With the exception of Asn651, which predominantly carries a high-mannose-type *N*-glycan, all sites feature complex-type *N*-glycans. Characterization of the *N*-glycan microheterogeneity based on intact *N*-glycopeptides revealed differences in relative abundance of the major *N*-glycoform at each site on N-Cdh derived from ΔPOMGnT1 compared with WT cells (Fig. 5C). All *N*-glycosylation sites (except for Asn651 and Asn692, which are both located at the stem region of the molecule) feature non-galactosylated complex-type *N*-glycans with a bisecting GlcNAc (GlcNAc(5)Man(3)±Fuc(1)) as the dominating composition on N-Cdh from ΔPOMGnT1 cells. Comparative and site-specific *N*-glycoproteomics of quantitative changes in the *N*-glycan microheterogeneity revealed a significant decrease in galactosylation (−27% on average) and sialylation (−16% on average) throughout the vast majority of *N*-glycosylation sites (only exception are Asn190 and Asn651) (Fig. 5C). This decrease in galactosylation and sialylation is associated with a significant increase of nongalactosylated *N*-glycan compositions that feature a bisecting GlcNAc (Fig. 5, B

and C). The site-specific relative changes of *N*-glycan traits on N-Cdh are shown in detail in Supporting information S11–S13 (Figs S6–S13 and Tables S7–S17). Overall, *N*-glycosylation of N-Cdh in ΔPOMGnT1 cells exhibits a reduction in the degree of galactosylation and sialylation with nongalactosylated complex-type *N*-glycans with a bisecting GlcNAc dominating.

To identify glycosyltransferases that could be responsible for the observed changes in the *N*-glycan profile of N-Cdh, we next measured the transcript levels of genes encoding for major glycosyltransferases of *N*-glycan processing using the nCounter technology (23). Mild reduction in the mRNA levels of the Golgi GlcNAc-transferases *MGAT1* (by ~21%), *MGAT2* (by ~13%), and *MGAT5* (by ~21%) was observed in ΔPOMGnT1 cells. Furthermore, a decrease in transcript levels of β1,4-galactosyltransferase 1 *B4GALT1* (by ~22%) as well as sialyltransferases *ST6GAL1* (by ~64%) and *ST3GAL3* (by ~69%) was detected (Table S18). Basal transcription levels of sialyltransferases are very low and close to the detection limit of the applied nCounter technology (Table S18). Therefore, we aimed to validate our results by qRT-PCR analysis including other α2,3-sialyltransferases that could contribute to the modification of N-Cdh (24). As shown in Figure 5D, a significant reduction in *B4GALT1* (by ~31%) and *ST6GAL1* (by ~33%) mRNA was confirmed in ΔPOMGnT1 cells, explaining the limited occurrence of respective *N*-glycans on N-Cdh in ΔPOMGnT1 cells. The changes in the mRNA levels of α2,3-sialyltransferases were found to be less consistent, possibly due to the limiting amount of transcripts. For *ST3GAL3* transcript levels, no significantly change could be detected, whereas *ST3GAL4* transcripts were reduced (by ~31%). The mRNA amount of *ST3GAL6* was increased (by ~50%). In view of the partial substrate specificities of α2,3-sialyltransferases, the latter might indicate even more complex compensatory reactions (24).


In summary, our data demonstrate that in POMGNT1-deficient cells, the *N*-glycan profile of N-Cdh is changed and that the observed alterations correlate to a great extent with transcriptional changes of respective *N*-glycan modifying enzymes.

In addition to *N*-glycans, N-Cdh carries nonelongated *O*-linked mannose residues (25, 26), which depend on a recently identified class of *O*-mannosyltransferases (tetratricopeptide repeats (TPR)-containing proteins; TMTC 1–3), rather than classic *O*-mannosylation (18). The *O*-mannose glycoproteome of N-Cdh revealed 15 *O*-mannose glycosylation sites—four of which have not been reported before (Table S6 and Supporting information SI4: Figs S14 and S15). However, no difference in the *O*-mannosylation pattern of N-Cdh between ΔPOMGnT1 and WT HEK293T cells was detected, excluding indirect effects on the activity of TMTCs.

#### Changes in N-Cdh N-glycosylation impact on its homotypic interactions in vitro

Hypo-*N*-glycosylation of N-Cdh increases the prevalence of cis N-Cdh dimers on the cell membrane, thereby stabilization of cell–cell contacts (21, 22). To determine whether the

## POMGNT1 impacts on N-cadherin-mediated cell-cell adhesion



**Figure 5. Deficiency in POMGNT1 affects N-glycosylation of N-cadherin.** *A*, comparative overlay of the electropherograms as obtained by xCGE-LIF after APTS labeling to evaluate N-glycan profile of N-Cdh derived from WT (red line) and ΔPOMGnT1 (blue line) HEK293T cells. The normalized signal intensity of APTS-labeled N-glycans (relative signal intensity (%), i.e., peak signal divided by the summed peak height of all quantifiable N-glycan peaks with signal-to-noise ratio >9) is plotted over their normalized migration time units (MTU"). Relevant peaks are numbered and annotated with corresponding glycan structures. A3 and A4 indicate three- and four-antennary N-glycan structures, respectively; while F indicates the presence of a fucose among the N-glycan structures. The asterisk denotes a peak of an internal migration time standard. *B*, overview of site-specific N-glycan microheterogeneity on extracellular domains (EC1–EC5) of N-Cdh, purified from WT and ΔPOMGnT1 HEK293T cells. Cartoon represents the molecular structure of five EC domains of N-Cdh, which form a β-barrel structure (brown and blue ribbons represent beta sheet and alpha helix, respectively). The positions of identified N-glycosylation sites are shown in red ribbons. For each N-glycosylation site, the major N-glycoform detected in WT (left) and ΔPOMGnT1 (right) is depicted. Values beneath the each glycan structure represent the relative abundance of this N-glycoform (quantitative values for each glycoform as proportions relative to the sum of all glycoforms detected) and the total of N-glycoforms detected on this site, respectively. Values for ΔPOMGnT1 are highlighted in black. Asterisk at position Asn190 indicates the scarcely N-glycosylated site (only one N-glycopeptide derived from WT N-Cdh could be identified). The molecular structure of N-Cdh was modeled by using open-source software UCSF Chimera Version 1.10.2. *A*, *B*, N-glycan structures were drawn with GlycoWorkbench Version 1.1, by following the guideline of the Consortium for Functional Glycomics. Pep = peptide moiety; green circle = mannose; yellow circle = galactose; blue square = N-acetylglucosamine; red triangle = fucose; purple diamond = N-acetylneuraminic acid. *C*, site-specific relative changes in the N-glycan traits (bisecting GlcNAc, sialylation, and galactosylation) in ΔPOMGnT1-derived N-Cdh. For each N-glycosylation site, quantitative changes in the N-glycan microheterogeneity are depicted as increase or decrease in ΔPOMGnT1-derived N-Cdh relative to the level in the WT. The quantities represent N-glycopeptide AUC values (EIC MS1) that were summed based on common N-glycan traits (N-glycopeptides carrying a bisecting GlcNAc, sialylation, and/or galactosylation). Since site N190 is only scarcely N-glycosylated, its microheterogeneity could not be quantified. *D*, qRT-PCR analysis of galactosyltransferase (B4GALT1) and sialyltransferases (ST3GAL3, ST3GAL4, ST3GAL6 and ST6GAL1) mRNA levels in WT and ΔPOMGnT1 cells. mRNA levels in ΔPOMGnT1 cells are calculated as %, considering the respective mRNA levels in WT cells as 100%. For normalization the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase was used. Assays were performed in triplicate from three biological replicates. Data are represented as means ± SD including all individual data points. Asterisks denote statistical significance in comparison with WT cells: \*\*  $p \leq 0.01$ , \*\*\*  $p \leq 0.001$ , n.s. not significant.

observed changes in *N*-glycosylation of N-Cdh also favor homotypic interactions, the adhesive properties of the recombinant extracellular domain of N-Cdh (see above) were analyzed using an *in vitro* bead aggregation assay (27). Dynabeads coated with the protein isolated from WT or  $\Delta$ POMGnT1 HEK293T cells were incubated with either CaCl<sub>2</sub> or EDTA as a control. Aggregation of beads, reflecting Ca<sup>2+</sup>-dependent homotypic interactions of the extracellular domain of N-Cdh, was recorded and quantified at specific time intervals over the course of 1 h. As shown in Figure 6A,  $\Delta$ POMGnT1-derived N-Cdh triggers the formation of larger aggregates in comparison with WT-derived N-Cdh, demonstrating that the adhesive properties of N-Cdh from  $\Delta$ POMGnT1 cells are enhanced.

Taken together, changes in cell–cell adhesion of  $\Delta$ POMGnT1 cells are due to a higher frequency of N-Cdh with less complex *N*-linked glycan structures that facilitate stronger homotypic interaction.

**Loss of function of POMGNT1 activates ERK and p38 signaling**

To further investigate how POMGNT1 deficiency modulates N-Cdh-mediated cell–cell adhesion, we explored possible changes in cellular signaling using a human phosphokinase array with 46 different kinases. Of all kinases examined, the extracellular signal-regulated kinase ERK1/2 and the mitogen-activated protein kinase p38 showed significantly enhanced


phosphorylation in  $\Delta$ POMGnT1 HEK293T cells when compared with WT cells (Fig. 7, A and B). Since dysregulation of DG and matriglycan biosynthesis has been associated with modulation of the ERK-MAPK pathway (28, 29), the identified changes were further validated by western blot. Consistent with the phosphokinase array data,  $\Delta$ POMGnT1 cells showed a significant increase in the phosphorylation levels of ERK1/2, with ERK2 being more affected (Fig. 7C, pERK1/2, lower band). Additionally, phosphorylation of the upstream MAP kinase kinase MEK1/2 (30) was found to be increased (Fig. 7, C and D) further corroborating that the ERK-MAPK pathway is activated in our  $\Delta$ POMGnT1 HEK293T cell model.

In order to shed further light on the link between ERK-MAPK activation and the observed changes in N-Cdh abundance and *N*-glycosylation, we took advantage of the MEK inhibitor U0126 that inhibits activation of the MAPK ERK1/2 (31). After 2 h of inhibitor treatment of  $\Delta$ POMGnT1 HEK293T cells, both ERK1/2 activation and the transcript levels of *B4GALT1*, *ST6GAL1*, and *CDH2* returned to WT levels (Fig. 7, E and F). To further corroborate these findings, the ERK-MAPK pathway was activated in WT HEK293T cells by expression of the constitutively active ERK2-R65S mutant protein (32) (Fig. 7G). Intriguingly, upon induction of ERK-MAPK signaling, mRNA levels of *B4GALT1*, *ST6GAL1*, and *CDH2* changed and became similar to those observed in  $\Delta$ POMGnT1 HEK293T cells (Fig. 7H). Overall, our data provide strong evidence of a causal relationship between ERK-MAPK signaling and changes in N-Cdh in the absence of POMGNT1 activity.

**Lack of POMGNT1 activity induces an EMT-related transcriptional response**


Increased expression of N-Cdh (33), transcriptional modulation of *N*-glycan modifying enzymes (34), and activation of the ERK-MAPK pathway (35) have been linked to epithelial–mesenchymal transition (EMT), a process that is of major importance during development, wound healing as well as tumor progression and metastasis (36). Therefore, the impact of POMGNT1 deficiency on the expression of EMT marker genes was investigated. As shown in Figure 8A, the mRNA levels of the epithelial markers *LAMA2* (encoding laminin subunit  $\alpha$ 2) and *CLDN6* (encoding claudin 6) are markedly decreased, whereas expression levels of the mesenchymal markers *ACTA2* (encoding actin  $\alpha$ 2) and *CDH2* (encoding N-Cdh) are significantly elevated in  $\Delta$ POMGnT1 compared with WT cells. Reintroduction of the *POMGNT1* gene reversed the observed transcriptional changes, thereby confirming their specificity. Moreover, mRNA levels of the EMT-inducing transcription factors (*Slug*, *Snail*, *TCF3*, *LEF1*) showed significant upregulation in  $\Delta$ POMGnT1 cells (Fig. S16).

EMT processes are associated with the upregulation of matrix metalloproteinases (MMPs), which represent a family of zinc-dependent endoproteases involved in degrading ECM components (37). A strong and specific increase of *MMP1*, *MMP3*, *MMP8*, and *MMP17* mRNA is observed in  $\Delta$ POMGnT1 cells (Fig. 8A). Also expression of




**Figure 6. N-Cadherin from POMGNT1-deficient cells shows enhanced homotypic interactions *in vitro*.** A, semiquantitative analysis of the mean size of dynabead aggregates coated with the extracellular domain of recombinant N-Cdh purified from WT (gray line) and  $\Delta$ POMGnT1 cells (black line). Protein-coated dynabeads were imaged following incubation in the presence of either CaCl<sub>2</sub> (solid lines) or EDTA (broken lines) at the indicated time intervals. Area of the aggregates was measured in units of pixels. Mean aggregate size is plotted against time. Assays were performed in quadruplicate from two independent experiments. Data are represented as means  $\pm$  SD. Asterisks denote statistical significance in comparison with WT cells: \*  $p \leq 0.05$ , \*\*  $p \leq 0.01$ . B, western blot analysis evaluating levels of protein from WT and  $\Delta$ POMGnT1 ( $\Delta$ ) bound to dynabeads. Dynabead-bound recombinant N-Cdh was eluted in SDS sample buffer (beads), resolved on a 10% SDS PAA gel. For detection on western blot, an anti-5x-His antibody was used. In addition, proteins before binding to beads (input) and unbound fractions (void) are shown.

## POMGNT1 impacts on N-cadherin-mediated cell-cell adhesion



**Figure 7. POMGNT1 deficiency activates ERK1/2 and p38 signaling pathways.** *A*, representative phosphokinase arrays performed with 500  $\mu$ g of whole-cell extract from WT (upper panels) and  $\Delta$ POMGnT1 cells (lower panels). Antibodies against phosphorylated protein kinases are spotted in duplicate. Signals for phosphorylated ERK1/2 and p38 are highlighted in boxes and denoted as 1 and 2, respectively. *B*, densitometry-based quantification of phosphorylated ERK1/2 and p38 signals detected in phosphokinase array for WT and  $\Delta$ POMGnT1 cells. Protein signals detected in  $\Delta$ POMGnT1 cells were normalized to the reference protein signal and subsequently normalized to the protein/reference signal ratio in WT cells. Analysis is based on two independent experiments. *C*, representative western blot analysis of p (phosphorylated)-ERK1/2 and -MEK1/2 levels in whole-cell lysates (corresponding to 20  $\mu$ g of total protein) from WT and  $\Delta$ POMGnT1 cells. Total levels of ERK1/2 and MEK1/2 were analyzed using protein-directed antibodies.  $\alpha$ -Tub was used as a loading control. *D*, densitometry-based quantification of phosphorylated ERK1/2 and MEK1/2 signals detected in western blot analysis for WT and  $\Delta$ POMGnT1 cells. Phosphorylated protein signals detected in  $\Delta$ POMGnT1 cells were normalized to the respective total protein signals and subsequently normalized to the phosphorylated/total protein signal ratio in WT cells. Data of four technical replicates are shown. *B*, *D*, protein levels of phosphorylated kinases in  $\Delta$ POMGnT1 cells are calculated as %, considering pixel density of the respective protein in WT cells as 100%. *E*, representative western blot analysis of p-ERK1/2 level (indicated as *arrow* and *star*) in whole-cell lysates (corresponding to 25  $\mu$ g of total protein) from DMSO-treated WT and DMSO or 10  $\mu$ M U0126-treated  $\Delta$ POMGnT1 cells. Total levels of ERK1/2 were analyzed using protein-directed antibodies.  $\alpha$ -Tub was used as a loading control. *F*, gene expression analysis by qRT-PCR of selected genes of N-glycan modifying enzymes and N-Cdh. Relative mRNA levels in DMSO-treated WT cells (white bars) were compared with levels detected in DMSO-treated  $\Delta$ POMGnT1 cells (gray bars), U0126-treated  $\Delta$ POMGnT1 cells (30 and 120 min treatment; strip gray bars and strip white bars, respectively). mRNA levels in U0126-treated  $\Delta$ POMGnT1 cells are calculated as %, considering mRNA levels of respective genes in DMSO-treated WT cells as 100%. Hypoxanthine-guanine phosphoribosyltransferase was used for normalization. Assays were performed in duplicate from three biological replicates. *G*, representative western blot analysis of p-ERK1/2 levels in of whole-cell lysates (corresponding to 25  $\mu$ g of total protein) from transiently transfected WT cells with either empty vector (WT + EV) or vector carrying constitutively active ERK2 (WT + ERK2-R65S) and from transiently transfected  $\Delta$ POMGnT1 cells with empty vector ( $\Delta$ POMGnT1 + EV). Total levels of ERK1/2 were analyzed using protein-directed antibodies. Analysis of whole-cell lysates with anti-HA antibody shows expression of HA-tagged ERK2-R65S in WT cells.  $\alpha$ -Tub was used as a loading control. *H*, gene expression analysis by qRT-PCR of selected genes of N-glycan modifying enzymes and N-Cdh. Relative mRNA levels in empty vector-transfected WT cells (white bars) were compared with levels detected in ERK2-R65S-transfected WT cells (strip gray bars) and empty vector-transfected  $\Delta$ POMGnT1 cells (gray bars). mRNA levels in ERK2-R65S-transfected WT and empty vector-transfected  $\Delta$ POMGnT1 cells are calculated as %, considering mRNA levels of respective genes in empty vector-transfected WT cells as 100%. Hypoxanthine-guanine phosphoribosyltransferase was used for normalization. Assays were performed in triplicate from three biological replicates. Data are represented as means  $\pm$  SD including all individual data points. Asterisks denote statistical significance in comparison with WT cells: \*\*  $p \leq 0.01$ , \*\*\*  $p \leq 0.001$ .  $\alpha$ -Tub,  $\alpha$ -Tubulin; n.s., not significant.





**Figure 8. *POMGNT1* deficiency induces changes in the expression of EMT-related genes in HEK293T cells.** *A*, gene expression analysis by qRT-PCR of selected EMT-related genes. Epithelial markers: *LAMA2* and *CLDN6*; mesenchymal markers: *ACTA2*, *CDH2* and *VIM*; matrix metalloproteinases (MMPs): *MMP1*, *MMP2*, *MMP3*, *MMP8* and *MMP17*; tissue inhibitors of MMPs (TIMPs): *TIMP1* and *TIMP2*. Relative mRNA levels in WT cells (white bars) were compared with levels detected in ΔPOMGnT1 cells (gray bars), *POMGNT1*-transfected ΔPOMGnT1 cells (ΔPOMGnT1 + *POMGNT1*; strip gray bars), and empty vector-transfected ΔPOMGnT1 cells (ΔPOMGnT1 + empty vector; strip white bars). Transcript levels in ΔPOMGnT1 cells are calculated as %, considering transcript levels of respective genes in WT cells as 100%. Hypoxanthine-guanine phosphoribosyltransferase was used for normalization. Assays were performed in duplicate with three dilutions from three biological replicates. *B*, representative MMP array performed with whole cell lysates (corresponding to 500 μg of total protein) from WT cells (left panel) and ΔPOMGnT1 cells (right panel). Antibodies against MMPs and TIMPs are spotted in duplicate. Signals for MMPs and TIMPs on the representative membranes are highlighted in boxes and denoted with numbers. *C*, densitometry-based quantification of MMP and TIMP signals detected in MMP array for WT and ΔPOMGnT1 cells. Protein signals detected in ΔPOMGnT1 cells were normalized to the reference protein signal and subsequently normalized to the protein/reference signal ratio in WT cells. Protein levels of MMPs and TIMPs in ΔPOMGnT1 cells are calculated in %, considering pixel density of the respective protein in WT cells as 100%. Analysis is based on two independent experiments. *A*, *C*, data are represented as means ± SD including all individual data points. Asterisks denote statistical significance in comparison with WT cells: \*  $p \leq 0.05$ , \*\*  $p \leq 0.01$ , \*\*\*  $p \leq 0.001$ , n.s. not significant.

metalloproteinase inhibitors (TIMPs; (38)) is affected. Likewise, analysis of the abundance of MMP proteins using a human MMP antibody array showed that MMP1, MMP3, and MMP8 levels are increased (Fig. 8, *B* and *C*).

To determine whether decreased *POMGNT1* activity also triggers an EMT-like transcriptional response in MEB patient-derived fibroblasts, mRNA levels of the above genes were assessed. Indeed, in comparison with control fibroblasts, epithelial markers (*LAMA2* and *CLDN6*) were found to be significantly reduced, whereas mesenchymal markers (*ACTA2*, *VIM* encoding vimentin and *FN* encoding fibronectin) were significantly elevated in MEB patients (Fig. 9*A*). In addition, the transcriptional modulation of *MMPs* and *TIMPs* was also comparable with the changes observed in ΔPOMGnT1 HEK293T cells with particularly large increase in transcript levels of *MMP1* and *MMP17* (Fig. 9*B*).


Altogether, our data demonstrate that lack of *POMGNT1* activity induces an EMT-like transcriptional response

resulting, *inter alia*, in elevated levels of ECM degrading enzymes.

## Discussion

α-Dystroglycanopathy is associated with the development of a variety of medical conditions, including muscular dystrophy and mild-to-severe changes in the central nervous system and the eyes. So far, several causative genes for α-dystroglycanopathy have been identified that are associated with the *O*-mannose glycosylation pathway of α-DG (10). Among those are *POMT1/POMT2* and *POMGNT1*, the major disease-causing factors of the Walker–Warburg syndrome (WWS; lacking classic *O*-mannose glycans), and MEB (no elongation of *O*-linked mannoses), respectively. Current knowledge regarding the predominant disease mechanism suggests that incomplete matriglycan biosynthesis impairs the binding of α-DG to extracellular matrix proteins such as laminin, resulting in damage to cell membrane integration and defective

## POMGNT1 impacts on N-cadherin-mediated cell–cell adhesion



**Figure 9. MEB patient-derived fibroblasts show changes in the expression of EMT-related genes.** Gene expression analysis by qRT-PCR of (A) epithelial (*LAMA2* and *CLDN6*) and mesenchymal (*ACTA2*, *FN1* and *VIM*) marker genes as well as (B) the indicated *MMPs* and *TIMPs*. Data were calculated as described in Figure 8A.

basement membranes (9). In recent years, it turned out that changes in classic *O*-mannosylation due to altered expression of *POMT2* impact also on epithelial cadherin (E-Cdh)-mediated cell–cell adhesion during murine embryonic development and in human gastric carcinoma (39, 40). However, whether the observed changes only apply to E-Cdh and *POMT2* is unclear, as are the underlying molecular mechanisms. Taking advantage of *POMGNT1*-deficient HEK293T cells and MEB patient-derived fibroblasts, we now provide further evidence that aberrant classic *O*-mannosylation can influence cadherin-mediated cell–cell adhesion. We demonstrate that loss of *POMGNT1* function results in (1) reinforced N-Cdh-mediated cell–cell adhesion and impaired cell migration potential; (2) increased levels of N-Cdh, and changed *N*-glycan structures on its extracellular domain, which in turn enhance its intrinsic adhesive properties; (3) activation of ERK1/2 and p38 signaling pathways and induction of transcriptional modulations, which are comparable with EMT-like events.

Changing cell migration behavior is a (patho)physiological process determined by the opposing forces that define cell–ECM and cell–cell interactions. In invasive cancers, decreased levels of *POMT1*, *POMT2*, and other enzymes of the classic *O*-mannosylation pathway correlate with high cell migration and invasion (29). But, low *POMGNT1* levels can also hinder cell migration. A *POMGNT1*-based MEB mouse model revealed clusters of granule cells within the cerebellum, which have failed to migrate during development (14). Further, Abbott and co-workers reported that knock-down of *POMGNT1* and *MGAT5B* impairs neuronal cell migration (41), and Lan and co-workers found that silencing of *POMGNT1* decreases cell proliferation and invasion in

glioblastoma (16). Therefore, *POMGNT1* deletion may also act as a break on invasion and migration; however, the direct molecular mechanism for the observed phenotypes is not fully understood. Our HEK293T cell model recapitulates the observed impact of *POMGNT1* on cell adhesion and migration observed in neuronal and glioblastoma cells and identifies increased N-Cdh-mediated cell–cell adhesion as one of the reasons that influences the cellular migration potential when *POMGNT1* activity is reduced. In addition to the increased amount of N-Cdh, its *N*-glycosylation pattern is changed to further promote N-Cdh homotypic interactions. In general, on N-Cdh from  $\Delta$ *POMGNT1*, *N*-glycans with a lower degree of galactosylation and sialylation, along with a slight increase in the abundance of bisecting GlcNAc, are observed. These changes are driven by the transcriptional regulation of specific glycosyltransferases, such as *B4GALT1* and *ST6GAL1*, which act as heteromeric complex in the successive addition of terminal  $\beta$ 1,4-linked galactose and  $\alpha$ 2,6-linked sialic acid to *N*-glycans (42); or probably *ST3GAL3* and *ST3GAL4*, which most likely contribute to the addition of  $\alpha$ 2,3-linked sialic acid to *N*-glycans of N-Cdh (24). Most interestingly, the changes in *N*-glycosylation are site-specific and especially site N402 in the EC3 domain contains less branched complex glycans, which have been reported to favor cell–cell adhesion. N402, along with N273 and N325, has previously been identified as one of the most relevant *N*-glycosylation sites that strongly increase cis-dimerization of N-Cdh when complexity of *N*-glycans is decreased (21). In line with previous findings of Salomé S. Pinho's group (in collaboration with our group) that in human gastric carcinomas, expression levels of *POMT2*

correlate with altered structures of *N*-glycans on E-cadherin (40), we now demonstrate a link between classic *O*-mannosylation and *N*-glycosylation of cadherins, which was for the first time analyzed in such depth.


Very recently it turned out that cadherins are also major targets of TMTC1-3, which add single nonextended *O*-linked mannoses to EC domains (18) that impact on cellular adherence (43). Indirect effects on TMTC-based *O*-mannosylation of N-Cdh due to lack of POMGNT1 could be excluded, as its *O*-mannosylation is not altered in our HEK293T cell model.

Increased expression of N-Cdh is part of a transformation process that mostly epithelial cells undergo known as epithelial-to-mesenchymal transition (33). EMT is inherent to physiological processes such as embryonic stem cell differentiation and development (44) and has further been associated with pathological conditions such as wound healing, fibrosis, and cancer stemness and progression (45–48). Key events of EMT are dissolution of epithelial cell–cell junctions, loss of the apical–basal polarity, and reorganization of the cytoskeleton as well as downregulation of epithelial gene expression in favor of genes that establish the more motile mesenchymal phenotype (36). Long regarded as an all-or-nothing event, EMT is now considered a transition suggesting a gradual and reversible process that does not exclusively concern epithelial cells (49). EMT does not necessarily include increased cell motility but can even lead to the opposite migration behavior (50, 51). Our results on POMGNT1-deficient HEK293T and fibroblast cells point to a partial EMT event that is accompanied by reduced expression of epithelial and increased expression for most of the mesenchymal markers tested. Nevertheless, transcript level of vimentin, which is characteristically upregulated in cells undergoing EMT (52), was found to be elevated only in MEB patient-derived fibroblasts. *VIM* transcripts are decreased in  $\Delta$ POMGnT1 HEK293T cells, and transcription is not restored after the introduction of exogenous *POMGNT1*. It is known that the nature of EMT-related changes in cell lines from different origins may vary (49), but reasons for the different modulation of *VIM* expression in the two cell types used in this study are currently unclear.

Very recently differential expression of POMGNT1 in human glioma cell lines has been reported to impact on the expression of some EMT marker proteins (17), further corroborating the general relevance and validity of our HEK293T cell model. We also observe a predominant induction of MMPs that is indicative of an EMT-like transition. Increased level of MMPs have been shown to be involved in degradation of the basement membrane in developmental processes (53, 54), wound healing (55), and cancer progression (37). Since breakdown of basement membranes is also one of the hallmark events in MEB disease (11) or  $\alpha$ -dystroglycanopathy in general, elevated levels of MMPs could increase ECM protein degradation and impede cell–ECM interactions further deteriorating the clinical outcome of these patients. A similar role has been suggested for MMP2 and MMP9 in physiological and pathological conditions involving members of the dystrophin glycoprotein complex (56).

In  $\Delta$ POMGnT1 cells, partial EMT correlates with sustained activation of ERK1/2 and p38 MAPK signaling, which has been associated with EMT induction (57). Whereas these pathways seem to be decisive for the EMT response observed, the source of its activation remains unclear. Although other factors cannot be excluded completely, the most likely candidate that induces ERK signaling is the dystrophin glycoprotein complex and DG in particular, which was suggested as a multifunctional adaptor, capable of interacting with components of the MAPK cascade including MEK and ERK (28). The role of DG on developmental and pathological EMT processes is well documented (54, 58). In line with our data,  $\alpha$ -DG glycosylation and its interaction with laminin have been suggested to enable  $\beta$ -DG to sequester ERK preventing it from translocating into the nucleus and promoting differentiation of a mesenchymal phenotype (59). Similar to dystroglycan, heteromeric integrins represent a major class of ECM receptors that control ERK signaling, and a cross talk between the two receptors is documented (60, 61). The influence of defects in *O*-mannosylation on integrin-mediated adhesion has been reported with variable outcome on cell migration in neuroblastoma and prostate carcinoma cells (29, 41). Interestingly, the work of Bao and co-workers suggests that *O*-mannosylation of  $\alpha$ -DG in prostate carcinoma cells counteracts integrin-mediated signaling in order to attenuate ERK activation (29). A similar scenario could apply to the  $\Delta$ POMGnT1 HEK293T model. Furthermore, to our best knowledge, so far no direct link between p38 and DG has been reported, while integrin-mediated activation of p38 is well documented in various systems (62). Thus, it will be an important future task to investigate the effects on integrin function in  $\Delta$ POMGnT1 cells.

Our study proved  $\Delta$ POMGnT1 HEK293T cells as an excellent system to study molecular details underlying  $\alpha$ -dystroglycanopathy. Our data suggest a model (Fig. 10) in which due to the loss of *O*-linked matriglycan on  $\alpha$ -DG, ERK and p38 signaling cascades are activated (directly or indirectly) in POMGNT1-deficient cells. As a consequence, EMT-like transcriptional events result *inter alia* in the induction of N-Cdh (*CDH2*) and MMPs. In addition, transcriptional



**Figure 10. Hypothetical model integrating the observed changes in POMGNT1-deficient cells.** For details, see Discussion.

## POMGNT1 impacts on N-cadherin-mediated cell–cell adhesion

modulation of N-glycan modifying enzymes contributes to increased N-Cdh homotypic interactions. In combination, these events result in enhanced cell–cell adhesion and disordered basement membranes, thereby contributing to the molecular pathogenesis of MEB disease. In prostate cancer cells, a reduction in the expression of *POMT1* and other glycosyltransferases, which are involved in the biosynthesis of the matriglycan (*B4GAT1*, *LARGE*), also leads to the activation of ERK1/2 (29). It is therefore tempting to speculate that phenotypes similar to those observed here for *POMGNT1* deficiency could also be caused by other enzymes of the O-mannosylation pathway in HEK293T cells. Pointing out the general relevance of our model for O-mannosylation defects will be an interesting question to be addressed in the future.

### Experimental procedures

#### Cell lines and culture conditions

HEK293T cells were maintained in high-glucose Dulbecco's modified Eagle's medium (DMEM) (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific), 1% nonessential amino acids (Thermo Fisher Scientific), and 1% Pen/Strep (Thermo Fisher Scientific) (referred to as complete media) at 37 °C in a humidified incubator with 5% of CO<sub>2</sub>.

#### Generation of TALEN-mediated *POMGNT1* knockout cells

Transcription Activator-Like Effector Nuclease (TALEN)-based constructs were designed utilizing the TAL Effector Nucleotide Targeter 2.0 online tool (63). Three TALEN constructs were selected, which target the ATG start codon of *POMGNT1*, the coding sequence of the D-X-D motif, and an intron–exon boundary upstream of the exon containing the D-X-D motif. All constructs present a restriction site close to the predicted TALEN cleavage site to allow screening of induced mutations by restriction fragment length polymorphism (RFLP) analysis. TALENs were assembled using the Golden Gate TALEN and TAL Effector Kit 2.0 (64) and employing pC-GoldyTALEN as the final expression vector (#100000024 and #38143, respectively; both from Addgene). Correct assembly of TALEN plasmid DNA was verified by restriction site analysis and sequencing and TALEN plasmids were transfected into WT HEK293T cells. Next, genomic DNA was isolated from transfected cells using the DNeasy Blood and Tissue Kit (Qiagen) according to manufacturer's instructions, and *POMGNT1* regions were amplified by PCR and digested using restriction sites close to the predicted TALEN cutting site. Detection of PCR products resistant to restriction indicated efficient cleavage by TALENs and was followed by dilutional cloning (1 cell/100 µl/96-well) and further genomic DNA isolation, PCR and RFLP analysis to obtain single cell knockouts. From the selected TALEN construct combinations, the one targeting the ATG start codon of *POMGNT1* (close to an *HpaII* restriction site; forward TALEN construct: TGGTGACCCGCCAAT, reverse TALEN construct: GGAAGCCCAGCCCCCTC) was the most efficient in inducing mutations and was therefore used for subsequent

dilutional cloning, PCR and RFLP. PCR analysis and sequencing of genomic DNA confirmed the knockout of *POMGNT1* (Fig. S1). *POMGNT1* knockout clones were furthermore evaluated by wheat germ agglutinin (WGA) enrichment for the absence of reactivity toward matriglycan on α-DG recognized by IIH6 antibodies (65) (see below). For *POMGNT1* complementation, pMBA40 was stably transfected into *POMGNT1* knockout HEK293T cells.

#### Plasmids

Plasmid encoding the constitutive active ERK2-R65S mutant and the corresponding empty vector were described previously (32).

To generate pMLHD7 for expression and subsequent purification of N-Cdh extracellular domain (EC) (EC-N-Cdh) C-terminally fused to a His<sub>8</sub>/Strep-tag, PCR was performed on mouse cDNA using primers forward: *acGGCGCGCC GACTGGGTCATCCCGCCAA* and reverse: *ccgCTCGAGT TATTTTTCGAACTGCGGGTGGCTCCAAGCGCTGTGAT GATGGTGGTGAGGTGATGGGCGCCCGTGCCAAGCC*. The encoded protein shows 96.8% identity with human N-Cdh. *AscI* and *XhoI* restriction sites are shown in italics, His<sub>8</sub>- and Strep-tag coding sequences are underlined, and the overlapping sequences to the extracellular domain of N-Cdh are depicted in bold. Purified PCR products were digested with *AscI* and *XhoI* and inserted into the pSecTag2 expression vector (Invitrogen).

Human full-length *POMGNT1* was amplified by PCR from cDNA extracted from HEK293T cells using primers forward: *cgaCTCGAGTGTCTGTTCTGGGGCTCCTGG* and reverse: *cttgaGCTAGCCCCGCCAATCCGGTATGGA*. *XhoI* and *NheI* restriction sites are shown in italics, and the overlapping sequences to human *POMGNT1* are depicted in bold. Purified PCR products were digested with *XhoI* and *NheI* and inserted into the pcDNA6/V5-His expression vector (Invitrogen) generating plasmid pMBA40 for *POMGNT1* complementation. All plasmids created in this study were verified by sequencing.

#### Transfection of HEK293T cells and generation of stable cell lines

Transfections with plasmid ERK2-R65S and the respective empty vector were carried out with TurboFect transfection reagent (Thermo Fisher Scientific) following the manufacturer's instructions. At 48 h posttransfection, cells were serum starved for 24 h and harvested.

Transfections with pMLHD7, pMBA40, and their respective empty vectors were performed with the calcium phosphate method (66). In short, 5 µg of plasmid DNA in 250 mM CaCl<sub>2</sub> was added dropwise to double-strength HBSS (280 mM NaCl, 2.8 mM Na<sub>2</sub>HPO<sub>4</sub>, 50 mM HEPES, pH 7.2) while mildly vortexing, and the final transfection solution was applied dropwise to cells with 40–50% confluency in 15 cm dishes. After 6 h the medium was replaced, and selection was performed with 500 µg/ml Zeocin (Invitrogen) for 4 weeks.

### U0126 treatment

MEK inhibitor U0126 (# S1102, Selleckchem) (10 mM in DMSO) was diluted in complete DMEM to a concentration of 10  $\mu$ M and applied to  $\Delta$ POMGnT1 cells, which were 70–80% confluent. Inhibitor and mock treatment was carried out for 30 and 120 min at 37 °C in a humidified incubator with 5% of CO<sub>2</sub>.

### Patient material

The study was performed in accordance with the declaration of Helsinki and approved by the Ethics Committee of the Medical Faculty Heidelberg. MEB skin fibroblasts were derived from a patient who presented with characteristic stigmata as mental retardation, blindness, spastic tetraplegia, contracture of limbs, and severely reduced proprioceptive reflex due to variant c.535\_751del (p.Asp179Argfs\*11) in the *POMGNT1* gene (NM\_017739.4). Control skin fibroblasts were obtained from two healthy anonymous donors. Fibroblasts were maintained in high-glucose DMEM (Thermo Fisher Scientific) supplemented with 10% FBS (PAN Biotech) and 1% Pen/Strep at 37 °C in a humidified incubator with 5% of CO<sub>2</sub>. Growth medium was changed every 72 h.

### Whole-cell lysate and crude membrane preparation

Cells at 90% confluency ( $\sim 5.0 \times 10^6$  cells) were washed with ice-cold phosphate-buffered saline (PBS) and lysed with 500  $\mu$ l of lysis buffer (10 mM Tris-HCl pH 7.6, 1% (w/v) SDS, 1 mM EDTA, supplemented with Halt protease and phosphatase inhibitor cocktail without EDTA (Thermo Fisher Scientific)). Lysis was performed for 30 min at 4 °C on a rotator with occasional vortexing, and whole-cell lysates were collected upon centrifugation (16,000g, 10 min, 4 °C).

For crude membrane extraction, cell pellets of  $\sim 5.0 \times 10^6$  cells were resuspended in 750  $\mu$ l of ice-cold hypotonic buffer [20 mM Tris-HCl pH 7.4, 10 mM NaCl, 1.5 mM MgCl<sub>2</sub>, supplemented with protease inhibitor cocktail without EDTA (Thermo Fisher Scientific) and 0.05 U/ $\mu$ l benzamide (Sigma Aldrich)], and homogenized by passing through a 27-gauge needle for ten times. Homogenized samples were subjected to centrifugation (16,000g, 15 min, 4 °C), and resulting pellets were resuspended in 500  $\mu$ l of hypotonic buffer. Protein concentration was measured using the BCA protein assay (Pierce).

### WGA pull-down

Around  $1.0 \times 10^7$  cells were incubated with 500  $\mu$ l of ice-cold homogenization buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% Triton X-100, 1 mM PMSF and 1 mM benzamide) for 20 min at 4 °C. Lysates were subjected to centrifugation (20,000g, 5 min, 4 °C), equivalent amounts of solubilized proteins from the supernatant (input) were added to 75  $\mu$ l of WGA-bound agarose beads (Vector Laboratories) and incubated o/n at 4 °C. After centrifugation (2000 rpm, 3 min, 4 °C), the supernatants (void) were removed, and beads were washed three times with 1 ml of ice-cold wash buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.1% Triton X-100). Bead-bound proteins were eluted by boiling in 100  $\mu$ l of 2.5 $\times$

SDS sample buffer (5 $\times$  sample buffer: 250 mM Tris-HCl pH 6.8, 500 mM DTT, 50% glycerol (v/v), 0.25% Bromophenol blue (w/v), 10% SDS (w/v)) (3 min, 95 °C) followed by centrifugation at 14,000 rpm for 1 min. In total, 30  $\mu$ l of eluted proteins was analyzed by SDS-PAGE and western blot.

### Heterologous protein expression and purification

For expression of EC-N-Cdh, HEK293T cells stably transfected with pMLHD7 were cultured for 72 h in serum-free medium. Upon initial centrifugation for removal of dead cells (1000g, 10 min, 4 °C) culture medium from two 90% confluent 15 cm dishes was filtered through a 1.2  $\mu$ m filter (Sartorius Stedim Biotech) and applied to a HisTrap column (1 ml bed volume, GE Healthcare) at a drop rate of 500  $\mu$ l/min at 4 °C for o/n. The column was washed with 10 ml of wash buffer (20 mM sodium phosphate (NaP<sub>i</sub>), 500 mM NaCl, 5 mM imidazole, pH 7.4), and elution of bound proteins was performed in ten fractions of 500  $\mu$ l elution buffer (20 mM NaP<sub>i</sub>, 500 mM NaCl, 500 mM imidazole, pH 7.4). Protein concentration of eluates was determined by BCA protein assay (Pierce) and analyzed by SDS-PAGE followed by Coomassie blue staining and western blot.

### Western blot

Protein samples were resolved on 10% SDS PAA gels and transferred on nitrocellulose membranes according to standard protocols. After blocking and incubation with respective antibodies, proteins were detected using ECL Prime Western Blotting Detection Reagent (GE Healthcare) and imager ImageQuant LAS 500 (GE Healthcare). Protein levels were normalized to the loading control using ImageJ software (version 1.52i, NIH). WT values that originate from independent experiments are in each case considered to be 100%, and the values for  $\Delta$ POMGnT1 replicates were calculated by normalization to the corresponding WT. Antibodies used: Rabbit anti-N-cadherin (#22018-1-AP, Proteintech), 1:1000; Mouse anti- $\alpha$ -dystroglycan, clone IIH6C4 (#05-293, Millipore), 1:2500; Rabbit anti- $\beta$ -dystroglycan (AP83, kind gift from K. Campbell), 1:1000; Mouse anti-Sec61 $\alpha$  (#sc-393182, Santa Cruz), 1:100; Mouse anti-Penta-His-tag (#P-21315, Thermo Fisher Scientific), 1:2000; Mouse anti-HA-tag (#26183, Thermo Fisher Scientific), 1:1000; Mouse anti- $\beta$ -tubulin (#T6199, Sigma Aldrich), 1:500; Rabbit anti-ERK1/2 (#9102, Cell Signaling), 1:1000; Rabbit anti-Phospho-ERK1/2(Thr202/Tyr204) (#9101, Cell Signaling), 1:1000; Rabbit anti-MEK1/2 (#9122, Cell Signaling), 1:1000; Rabbit anti-Phospho-MEK1/2(Ser217/221) (#9121, Cell Signaling), 1:1000; Goat anti-rabbit HRP-conjugated IgG (#12-348, Sigma Aldrich), 1:5000; Rabbit anti-mouse HRP-conjugated IgG (#AP160P, Sigma Aldrich), 1:5000.

### Cell proliferation and migration assay

Cell proliferation and migration were monitored by the xCELLigence system (ACEA Biosciences) according to manufacturer's instructions. The xCELLigence system is a real-time, nonlabeled, impedance-based cell analysis system that

## POMGNT1 impacts on N-cadherin-mediated cell–cell adhesion

allows cell proliferation and migration to be monitored in a continuous and quantitative manner.

To monitor proliferation, cells from exponential-phase cultures were detached using 0.05% Trypsin-EDTA (Invitrogen), counted with a Scepter 2.0 device (Merck-Millipore), and  $2.0 \times 10^4$  cells were seeded in each well of a 96-well E-Plate in a final volume of 200  $\mu$ l complete growth medium. The xCELLigence station was placed in a standard cell culture incubator, and the cell index was monitored every 15 min over a period of 90 h. The background impedance of the E-Plate was determined with complete growth medium alone.

Cell migration was monitored using a 16-well cell invasion/migration plate with each well consisting of an upper and a lower chamber separated by a microporous membrane containing randomly distributed 8  $\mu$ m pores. Cells deprived of FBS for 24 h were seeded in the upper chambers at a density of  $7.5 \times 10^3$  cells/well in a total volume of 180  $\mu$ l of FBS-free media. The lower chamber was filled with 160  $\mu$ l of complete medium. After mounting both chambers to each other, the plate was loaded into the xCELLigence station and placed into a standard cell culture incubator. Impedance readout, expressed as cell index, was executed every 15 min over a period of 90 h. Cell proliferative and migratory responses were determined by calculating the mean cell index value and slope of the line between two given time points. Each subpopulation was measured in quadruplicate.

### Cell–ECM and cell–cell adhesion assay

ECM adhesion was monitored using the Milliccoat ECM Screening Kit (Millipore). Prior to each experiment, cells were deprived of FBS for 24 h. To initiate the experiment, subconfluent cell monolayers were treated with 10 mM EDTA in PBS to obtain a single cell suspension. Cells were washed twice with FBS-free medium, added at a density of  $8.0 \times 10^4$  cells per 96-well in a total volume of 180  $\mu$ l, and allowed to adhere for 1 h at 37 °C. Unattached cells were removed by washing three times with ice-cold PBS containing 1 mM CaCl<sub>2</sub> and 1 mM MgCl<sub>2</sub>. Attached cells were fixed with freezer-cold 100% methanol. Adherent cells were stained with 0.2% (v/v) crystal violet, washed, and the staining was released according to manufacturer's instructions. To determine the relative number of bound cells, OD<sub>600</sub> recorded for BSA-coated wells was subtracted from OD<sub>600</sub> recorded for ECM-coated wells. Percentage of adhesion of  $\Delta$ POMGnT1 cells to ECM was calculated by taking adhesion of WT as 100%.

To analyze cell–cell adhesion,  $1.0 \times 10^4$  cells/well were plated in flat-bottom 96-well plates and allowed to grow to a confluent monolayer for 48 h. Single cell suspensions ( $5.0 \times 10^4$  cells/well) were added on top of each cell monolayer and allowed to adhere for 20 min at 37 °C. Subsequent steps including washing, fixing, staining, and OD<sub>600</sub> measurement were performed as mentioned above.

To analyze N-Cdh-mediated cell–cell adhesion, WT or  $\Delta$ POMGnT1 cells deprived of FBS o/n were incubated for 30 min with 15  $\mu$ g/ml human anti-N-Cdh antibody (#22018-1-AP, Proteintech) and seeded on anti-N-Cdh antibody

pretreated confluent cell monolayers. As a negative control, both single cell suspensions and cell monolayers were pretreated with anti-human IgG antibody. The adhesion assay was performed as described above. The absorbance measured was normalized against the mean absorbance of wells, where no cells were added. The quantification of respective cell–cell adhesion was represented as relative adhesion in %, considering relative adhesion of WT to WT cells pretreated with anti-human IgG antibody as 100%.

For all assays, WT values that originate from independent experiments are in each case considered to be 100%, and the values for  $\Delta$ POMGnT1 replicates were calculated by normalization to the corresponding WT.

### Bead aggregation assay

To detect the homophilic interactions of the recombinant extracellular domain (EC) of N-Cdh, bead aggregation assays were conducted as previously described with slight modifications (27). Briefly, EC-N-Cdh protein purified from WT and  $\Delta$ POMGnT1 HEK293T cells (see above) was incubated with prewashed Dynabeads (Invitrogen) at a ratio of 40  $\mu$ g of protein per 40  $\mu$ l of bead suspension o/n at 4 °C. Next, beads were washed twice in binding buffer (50 mM Tris-HCl pH 7.2, 100 mM NaCl, 10 mM KCl and 0.2% BSA) and resuspended in 200  $\mu$ l of the same buffer. Bead suspensions were briefly sonicated and split into two tubes, and either 2 mM CaCl<sub>2</sub> or 2 mM EDTA was added to each tube for the “calcium” and “no-calcium” conditions, respectively. The samples were incubated at room temperature. Bead aggregation was assessed by spotting 10  $\mu$ l of each condition on glass depression slides at various time points, and images were captured on an Axiostar microscope (Zeiss) at 10-fold magnification. Bead aggregates were quantified using ImageJ software (version 1.52i, NIH). Briefly, images were thresholded, the area of the detected aggregated particles was measured in units of pixels, and the average size was calculated. Assays were repeated three times using two independent protein purifications, and their mean aggregate size ( $\pm$ SD) at each time point was plotted. To quantify protein coupled to the beads, 100  $\mu$ l of bead suspension was heated with SDS sample buffer (10 min, 95 °C), and the supernatant was analyzed by SDS-PAGE and western blot.

### Proteomics

Proteome analysis of WT and  $\Delta$ POMGnT1 cells was performed in five replicates. Cells were grown to 90% confluency in 15 cm dishes and lysed in 1 ml lysis buffer (PBS with 1% Triton X-100 (v/v), 1 mM PMSF, 1 mM benzamide, 0.25 mM TLCK, 50  $\mu$ g/ml TPCK, 20  $\mu$ g/ml antipain, 1  $\mu$ g/ml leupeptin, 1  $\mu$ g/ml pepstatin) for 30 min on ice. Supernatants of whole-cell lysates were collected after centrifugation (20,000g, 10 min, 4 °C), sonicated (Branson Sonifier 450 at 60% Duty Cycle, Level 6 Output Control) for 15 min, and resolved on 10% SDS PAA gels. Gels were washed four times in ddH<sub>2</sub>O (200 ml, 30 min), stained in a colloidal Coomassie solution (5% aluminium sulphate hydrate (w/v), 10% ethanol (v/v), 0.02% Coomassie Brilliant Blue G-250 (w/v), 2% phosphoric acid (v/

v)) for 1–2 h, and destained o/n in 500 ml ddH<sub>2</sub>O. Proteins were isolated from respective gel pieces, carbamidomethylated, subjected to tryptic digestion (1:50), and acidified with 1% trifluoroacetic acid. Peptide analysis was performed on a liquid chromatography–mass spectrometer (LC-MS), therefore an UltiMate 3000 nanoRSLC (Thermo Fisher Scientific) was used coupled to an LTQ Orbitrap Elite MS (Thermo Fisher Scientific). Peptides were trapped and desalted on a C18-column (5 µm Acclaim PepMap100 300 µm × 5 mm, Thermo Fisher Scientific) at a flow rate of 30 µl/min with solution A [1% acetonitrile (ACN), 1% formic acid (FA)]. After 3 min of loading, peptides were separated on an analytical column (2 µm Acclaim PepMap RSLC 75 µm × 25 cm, Thermo Fisher Scientific) using a 150 min method and an effective gradient of solution A (1% ACN, 5% DMSO, 0.1% FA) and B (90% ACN, 5% DMSO, 0.1% FA): 3% to 40% B in 110 min; 40% to 90% B in 10 min; flow rate: 300 nl/min. Full-scan mass spectra were acquired in the Orbitrap analyzer in the positive ion mode at 60,000 resolution at 200 m/z. A lock mass of 445.120020 m/z was used for internal recalibration, followed by collision-induced dissociation fragmentation of the 30 most intense ions (top 30). Spectra were acquired in the centroid mode using an ion trap detector. MS data were analyzed by MaxQuant (version 1.6.5.0) (67) and Andromeda search engine (68) with standard settings except noted otherwise. The UniProt human database was used (downloaded on July 08/2019, reviewed database entries: 26,468). Carbamidomethylation of cysteine was set as a fixed modification. Methionine oxidation, asparagine/glutamine deamidation, protein N-terminus acetylation, and serine/threonine mono hexosylation were set as variable modifications. A minimal peptide length of seven amino acids and at maximum two miscleavages (trypsin/p) were allowed. The maximum protein, peptide, and site false discovery rates were set to 0.05. “Re-quantify” and “Match between runs (2 min)” were activated. LFQ intensities of the proteins were used and analyzed in the program Perseus (label-free quantification). Only identified by site, reverse and potential contaminants were filtered out. LFQ intensities were logarithmized to the base of 2. Multiscatter plot and histograms were performed with that data. For the analysis of the principle component analysis (PCA) and the heat map, the candidates were filtered, only proteins with valid values in all ten samples were allowed. The MS proteomics data have been deposited to the ProteomeXchange Consortium *via* the PRIDE (69) Archive repository with the data set identifier PXD021321. Raw data sample code: V-E-750: A (CTL(A)); V-E-751: B (CTL(B)); V-E-752: C (CTL(C)); V-E-753: D (CTL(D)); V-E-754: E (CTL(E)); V-E-760: K (POMGNT1 –/– (A)); V-E-761: L (POMGNT1 –/– (B)); V-E-762: M (POMGNT1 –/– (C)); V-E-763: N (POMGNT1 –/– (D)); V-E-764: O (POMGNT1 –/– (E)).

#### **N- and O-mannose glycoproteomics of N-cadherin**

Sample preparation, measurement, and glycoproteomic analysis were conducted as previously described in Hoffmann *et al.* (70). Briefly, EC-N-Cdh purified from WT and ΔPOMGnT1 HEK293T cells was proteolytically digested for 8 h at 37 °C using

trypsin (enzyme:substrate ratio 1:30) as well as proteinase K (enzyme:substrate ratio 1:10). Specifically, for O-mannose glycoproteomics, proteins were treated with PNGase F (Sigma Aldrich) (0.5 U, 37 °C, 8 h) prior to the proteolytic digest. Enrichment of N-linked and O-mannosyl glycopeptides was performed using spin-cotton HILIC SPE. Enriched glycopeptides were analyzed by reverse-phase liquid chromatography coupled online to RP-LC-ESI-OT MS/MS (Thermo Fisher Scientific) using two higher-energy collision dissociation fragmentation regimes (HCD.low and HCD.step). Glycopeptide mass spectra were analyzed using glyXtoolMS (in-house developed software) (71), as well as Byonic and Byologic (both from Protein Metrics). Data are provided in Table S6. All MS glycoproteomics raw data have been deposited to the MassIVE repository under the data set identifier MSV000085243.

#### **N-glycome analysis of N-cadherin**

N-glycan structures were analyzed by xCGE-LIF, as previously described with slight modifications (72–74). Briefly, proteins were linearized and disulfide bonds were reduced using SDS and DTT for 10 min at 60 °C. N-glycans were released from protein backbone by PNGase F incubation (Sigma Aldrich) for 12 h at 37 °C. Released N-glycans were labeled with 8-aminopyrene-1,3,6-trisulfonic acid (APTS, Sigma Aldrich), followed by a sample cleanup step (HILIC SPE) using glyXbeads (glyXera) to remove excess label, salt, and other impurities. The purified labeled N-glycans were analyzed by xCGE-LIF. Using the glycoanalysis system glyX-box (incl. kits, software (glyXtool v5.3.1) and database (glyX-base); glyXera), the generated N-glycan electropherogram data (migration times) were normalized to an internal standard, resulting in a so-called “N-glycan fingerprint” with highly reproducible standardized migration time units. Subsequently, glyXtool was utilized for automated peak picking, integration, and relative quantification, as well as for the structural assignment of the N-glycan peaks by migration time matching to the N-glycan database glyXbase. To confirm N-glycan compositions and linkages, a comprehensive exoglycosidase sequencing was performed, using the enzymes α-(2–3) sialidase (Prozyme), α-(2–3,6,8) sialidase (Prozyme), α-(1–2,3,4,6) fucosidase (Prozyme), β-(1–4,6) galactosidase (Prozyme), and α(1–2,3,6) mannosidase (Prozyme). All exoglycosidase digests were carried out at 37 °C and at the reaction conditions recommended by the respective enzyme supplier. Each exoglycosidase enzyme was carefully tested for activity, specificity, and possible side activities. Please note, differing from the original protocol, HEK293T cell-derived EC-N-Cdh samples were desalted prior to N-glycan release. To this end, each N-Cdh sample was desalted against PBS using Amicon centrifugal filters with a 3 kDa molecular weight cutoff according to the manufacturer’s protocol (Merck-Millipore). Unprocessed xCGE-LIF N-glycomics raw data are available upon request.

#### **Quantitative real-time PCR**

Total RNA from cells was extracted using the Universal RNA Purification Kit (Roboklon) according to the

## POMGNT1 impacts on N-cadherin-mediated cell–cell adhesion

manufacturer's recommendations. In total, 2 µg of total RNA was reverse transcribed into cDNA using the FastGene-Scriptase Basic cDNA Kit (Tiangen Biotech) with random Oligo(dT) primers following manufacturer's instructions. Quantitative real-time PCR was performed on a Rotor-Gene Q (Qiagen) using the qPCR BIO SyGreen Mix Lo-ROX (PCR Biosystems). PCR reactions were performed as follows: 95 °C for 30 s followed by 40 cycles of 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s in a final volume of 15 µl containing 3 µl of 1:10 cDNA dilution and 0.5 mM of respective oligonucleotides. As technical replicates and for determination of qRT-PCR efficiency, 1:100 and 1:1000 cDNA dilutions were included. Only qRT-PCR reactions with efficiencies ranging from 0.9 to 1.1 were further analyzed. Gene expression was normalized to expression of the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase. For calculation of relative gene expression shown in [Figure 3, D and G](#), [Figures 8A and 9](#), the standard curve-based method was used. Relative gene expression shown in [Figures 5D and 7, F and H](#) was calculated using double-delta Ct analysis. The primers are provided in [Table S19](#).

### nCounter gene expression profiling

To address changes at the transcript level, multiplex analysis with the nCounter System (Nanostring Technologies) was performed. This technique is probe-based, does not require an enzymatic reaction, and thereby leads to very precise results. A gene-specific capture probe hybridizes with its target RNA, which subsequently binds to a uniquely color-coded reporter probe for automated counting. Total RNA was isolated from  $1 \times 10^6$  HEK293T and fibroblast cell lines by using the RNeasy Mini Kit (Qiagen) in combination with the QIAshredder system (Qiagen) according to the manufacturer's protocol. In total, 50 ng of total RNA was used per hybridization reaction to determine the transcript levels of glycosyltransferases. Further processing was conducted at the nCounter Core Facility Heidelberg using the nCounter SPRINT system and nCounter Elements chemistry as described (75). Probe design for the glycosyltransferase genes and reference genes are given on request. Data normalization was performed with the nSolver Analysis Software 3.0 (nanoString Technologies).

### Human phosphokinase and MMP array

Phosphorylation of several kinases and expression levels of MMPs were analyzed using Proteome Profiler Human Phospho-Kinase Array Kit (R&D Systems) and Human MMP Antibody Array Kit (Abcam), respectively, according to the manufacturer's instructions. Briefly,  $\sim 2.0 \times 10^6$  cells were grown in complete media for 48 h, lysed, and protein concentration was measured using the BCA protein assay (Pierce). For both arrays, preblocked nitrocellulose membranes were incubated with cellular lysate (corresponding to 500 µg of total protein) o/n at 4 °C and subsequently washed and incubated with biotin-conjugated antibodies and HRP-conjugated streptavidin. Membranes were then incubated with Chemi

Reagent Mix and developed in ImageQuant LAS 500 imaging system (GE Healthcare). For protein-level quantification, the integrated optical density (IOD) of each array spot was quantified using ImageJ software (version 1.52i, NIH). IOD values were normalized to those of the positive controls on each membrane and corrected for background signal. Relative expression levels of proteins in two groups of cells were calculated as %. The relative amount of the respective protein in WT was considered as 100%.

### Immunofluorescence

For actin staining, cells were seeded on poly-L-lysine-coated coverslips and fixed after 72 h with prewarmed paraformaldehyde (3% in PBS) for 10 min. Subsequently, cells were washed with PBS and permeabilized for 5 min with 0.1% Triton X-100 in PBS and blocked with 5% ChemiBlocker (Merck-Millipore) in PBS for 30 min. Coverslips were incubated with Rhodamine Phalloidin (Thermo Fisher Scientific) and DAPI (Sigma Aldrich) both at 1:1000 dilution in blocking solution for 1 h at 37 °C in a wet chamber, washed three times with PBS, and mounted in Mowiol (Polysciences). Images were acquired using an Olympus IX81 inverted microscope (Olympus) equipped with a Spectra Xlight system (Lumencor), Dualband GFP/mCherry sbx ET and QuadDAPI/FITC/Cy3/Cy5 sbx HC filter sets, an UPLSAPO 20×/0.75 Air objective lens (Olympus), an ORCA-R2 camera (Hamamatsu) and CellSens dimension software (Olympus). Image brightness and contrast were linearly adjusted for publication using ImageJ software (version 1.52i, NIH).

### Statistical analysis

For statistical testing, two-sided paired Student's *t*-tests were performed using Excel. Error bars represent standard deviations of at least three independent experiments unless indicated otherwise.

### Data availability

MS proteomics data have been deposited to the ProteomeXchange Consortium *via* the PRIDE (69) partner repository with the data set identifier PXD021321. MS glycoproteomics raw data have been deposited to the MassIVE repository under the data set identifier MSV000085243. Unprocessed xCGE-LIF N-glycomics raw data are available upon request. All other data described are contained within the article.

---

*Supporting information*—This article contains [supporting information](#).

*Acknowledgments*—We are very grateful to Mark Lommel for cloning plasmid pMLHD7 and his help in the generation and characterization of TALEN-mediated knockout cells. We thank the Joachim Wittbrodt's group for advice and support in TALEN technology; Kevin P. Campbell for providing the anti-β dystroglycan antibody; David Engelberg for providing *ERK2* plasmids; and Ricardo Carvalho and the ZMBH Imaging Facility (Heidelberg University, Germany) for excellent technical support



in microscopy. We thank Udo Reichl for generously providing research infrastructure and support to E. R.

**Author contributions**—S. I. N., M. F. B., P. R. W., T. R., E. R., C. T., and S. S. conceived and designed the experiments. S. I. N., M. H., R. H., P. R. W., M. F. B., C. H., and N. H. performed the experiments. In particular: S. I. N. performed adhesion and bead aggregation assays, qRT-PCR, as well as kinase and MMP arrays. M. H. and R. H. performed glycoproteome and glycome analysis; P. R. W. performed mass spectrometry; M. F. B. performed proliferation and migration assays; C. H. performed immunofluorescence and WGA pull-down assay; and N. H. performed nCounter gene expression profiling. S. I. N., M. H., N. R., P. R. W., M. F. B., C. H., R. H., N. H., E. R., and S. S. analyzed and evaluated the data. S. I. N., N. R., and S. S. wrote the article.

**Funding and additional information**—This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—Project-ID STR 443/6-1 (to S. S.), RA2992/1-1 (to E. R.), RU 747/1-1 (to T. R.), TH1461/7-1 (to C. T.)—Forschungsgruppe FOR 2509. P. R. W. is currently funded by the GRK 2155 ProMoAge.

**Conflict of interest**—The authors declare that they have no conflicts of interest with the contents of this article.

**Abbreviations**—The abbreviations used are:  $\alpha/\beta$ -DG,  $\alpha/\beta$ -dystroglycan; DMEM, Dulbecco's modified Eagle's medium; E/N-Cdh, E(epithelial)/N(neural)-cadherin; ECM, extracellular matrix; EMT, epithelial-mesenchymal transition; ER, endoplasmic reticulum; FBS, fetal bovine serum; HILIC SPE, hydrophilic interaction liquid chromatography solid-phase extraction; MEB disease, muscle-eye-brain disease; MMPs, matrix metalloproteinases; PBS, phosphate-buffered saline; PCA, principle component analysis; qRT-PCR, quantitative real-time PCR; RFLP, restriction fragment length polymorphism; RP-LC-ESI-OT MS/MS, reverse-phase liquid chromatography coupled online to electrospray ionization orbitrap tandem mass spectrometer; TALENs, transcription activator-like effector nucleases; WGA, wheat germ agglutinin; WT, wild type; xCGE-LIF, multiplexed capillary gel electrophoresis with laser-induced fluorescence detection.

**References**

1. Corfield, A. P., and Berry, M. (2015) Glycan variation and evolution in the eukaryotes. *Trends Biochem. Sci.* **40**, 351–359
2. Moremen, K. W., Tiemeyer, M., and Nairn, A. V. (2012) Vertebrate protein glycosylation: Diversity, synthesis and function. *Nat. Rev. Mol. Cell Biol.* **13**, 448–462
3. Pereira, M. S., Alves, I., Vicente, M., Campar, A., Silva, M. C., Padrão, N. A., Pinto, V., Fernandes, A., Dias, A. M., and Pinho, S. S. (2018) Glycans as key checkpoints of T cell activity and function. *Front. Immunol.* **9**, 2754
4. Pinho, S. S., and Reis, C. A. (2015) Glycosylation in cancer: Mechanisms and clinical implications. *Nat. Rev. Cancer* **15**, 540–555
5. Theodore, M., and Morava, E. (2011) Congenital disorders of glycosylation: Sweet news. *Curr. Opin. Pediatr.* **23**, 581–587
6. Zielinska, D. F., Gnad, F., Wisniewski, J., and Mann, M. (2010) Precision mapping of an *in vivo* N-glycoproteome reveals rigid topological and sequence constraints. *Cell* **141**, 897–907
7. Neubert, P., and Strahl, S. (2016) Protein O-mannosylation in the early secretory pathway. *Curr. Opin. Cell Biol.* **41**, 100–108
8. Endo, T. (2019) Mammalian O-mannosyl glycans: Biochemistry and glycopathology. *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* **95**, 39–51

9. Yoshida-Moriguchi, T., and Campbell, K. P. (2015) Matriglycan: A novel polysaccharide that links dystroglycan to the basement membrane. *Glycobiology* **25**, 702–713
10. Endo, T. (2014) Glycobiology of  $\alpha$ -dystroglycan and muscular dystrophy. *J. Biochem.* **157**, 1–12
11. Yoshida, A., Kobayashi, K., Manya, H., Taniguchi, K., Kano, H., Mizuno, M., Inazu, T., Mitsuhashi, H., Takahashi, S., Takeuchi, M., Herrmann, R., Straub, V., Talim, B., Voit, T., Topaloglu, H., *et al.* (2001) Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase. *Pomgnt1. Dev. Cell* **1**, 717–724
12. Xiong, H., Kobayashi, K., Tachikawa, M., Manya, H., Takeda, S., Chiyonobu, T., Fujikake, N., Wang, F., Nishimoto, A., Morris, G. E., Nagai, Y., Kanagawa, M., Endo, T., and Toda, T. (2006) Molecular interaction between fukutin and POMGNT1 in the glycosylation pathway of  $\alpha$ -dystroglycan. *Biochem. Biophys. Res. Commun.* **350**, 935–941
13. Kuwabara, N., Manya, H., Yamada, T., Tateno, H., Kanagawa, M., Kobayashi, K., Akasaka-Manya, K., Hirose, Y., Mizuno, M., Ikeguchi, M., Toda, T., Hirabayashi, J., Senda, T., Endo, T., and Kato, R. (2016) Carbohydrate-binding domain of the POMGNT1 stem region modulates O-mannosylation sites of  $\alpha$ -dystroglycan. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 9280–9285
14. Liu, J., Ball, S. L., Yang, Y., Mei, P., Zhang, L., Shi, H., Kaminski, H. J., Lemmon, V. P., and Hu, H. (2006) A genetic model for muscle-eye-brain disease in mice lacking protein O-mannose 1,2-N-acetylglucosaminyltransferase (POMGNT1). *Mech. Dev.* **123**, 228–240
15. Hu, H., Yang, Y., Eade, A., Xiong, Y., and Qi, Y. (2007) Breaches of the pial basement membrane and disappearance of the glia limitans during development underlie the cortical lamination defect in the mouse model of muscle-eye-brain disease. *J. Comp. Neurol.* **501**, 168–183
16. Lan, J., Guo, P., Lin, Y., Mao, Q., Guo, L., Ge, J., Li, X., Jiang, J., Lin, X., and Qiu, Y. (2015) Role of glycosyltransferase PomGnT1 in glioblastoma progression. *Neuro Oncol.* **17**, 211–222
17. Liu, Q., Xue, Y., Chen, Q., Chen, H., Zhang, X., Wang, L., Han, C., Que, S., Lou, M., and Lan, J. (2017) PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma. *Oncol. Rep.* **38**, 2911–2918
18. Larsen, I. S. B., Narimatsu, Y., Joshi, H. J., Siukstaite, L., Harrison, O. J., Brasch, J., Goodman, K. M., Hansen, L., Shapiro, L., Honig, B., Vakhrushev, S. Y., Clausen, H., and Halim, A. (2017) Discovery of an O-mannosylation pathway selectively serving cadherins and protocadherins. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 11163–11168
19. Narimatsu, Y., Joshi, H. J., Schjoldager, K. T., Hintze, J., Halim, A., Steentoft, C., Nason, R., Mandel, U., Bennett, E. P., Clausen, H., and Vakhrushev, S. Y. (2019) Exploring regulation of protein O-glycosylation in isogenic human HEK293 cells by differential O-glycoproteomics. *Mol. Cell Proteomics* **18**, 1396–1409
20. Wheelock, M. J., and Johnson, K. R. (2003) Cadherins as modulators of cellular phenotype. *Annu. Rev. Cell Dev. Biol.* **19**, 207–235
21. Guo, H. B., Johnson, H., Randolph, M., and Pierce, M. (2009) Regulation of homotypic cell-cell adhesion by branched N-glycosylation of N-cadherin extracellular EC2 and EC3 domains. *J. Biol. Chem.* **284**, 34986–34997
22. Langer, M. D., Guo, H., Shashikanth, N., Pierce, J. M., and Leckband, D. E. (2012) N-glycosylation alters cadherin-mediated intercellular binding kinetics. *J. Cell Sci.* **125**, 2478–2485
23. Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., James, J. J., Maysuria, M., Mitton, J. D., Oliveri, P., Osborn, J. L., *et al.* (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. *Nat. Biotechnol.* **26**, 317–325
24. Qi, F., Isaji, T., Duan, C., Yang, J., Wang, Y., Fukuda, T., and Gu, J. (2020) ST3GAL3, ST3GAL4, and ST3GAL6 differ in their regulation of biological functions via the specificities for the  $\alpha$ 2,3-sialylation of target proteins. *FASEB J.* **34**, 881–897
25. Winterhalter, P. R., Lommel, M., Ruppert, T., and Strahl, S. (2013) O-glycosylation of the non-canonical T-cadherin from rabbit skeletal muscle by single mannose residues. *FEBS Lett.* **587**, 3715–3721

## POMGNT1 impacts on N-cadherin-mediated cell–cell adhesion

26. Vester-Christensen, M. B., Halim, A., Joshi, H. J., Steentoft, C., Bennett, E. P., Levery, S. B., Vakhrushev, S. Y., and Clausen, H. (2013) Mining the O-mannose glycoproteome reveals cadherins as major O-mannosylated glycoproteins. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 21018–21023
27. Emond, M. R., and Jontes, J. D. (2014) Bead aggregation assays for the characterization of putative cell adhesion molecules. *J. Vis. Exp.* **92**, e51762
28. Spence, H. J., Dhillon, A. S., James, M., and Winder, S. J. (2004) Dystroglycan, a scaffold for the ERK-MAP kinase cascade. *EMBO Rep.* **5**, 484–489
29. Bao, X., Kobayashi, M., Hatakeyama, S., Angata, K., Gullberg, D., Nakayama, J., Fukuda, M. N., and Fukuda, M. (2009) Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 12109–12114
30. Lavoie, H., Gagnon, J., and Therrien, M. (2020) ERK signalling: A master regulator of cell behaviour, life and fate. *Nat. Rev. Mol. Cell Biol.* **21**, 607–632
31. DeSilva, D. R., Jones, E. A., Favata, M. F., Jaffee, B. D., Magolda, R. L., Trzaskos, J. M., and Scherle, P. A. (1998) Inhibition of mitogen-activated protein kinase blocks T cell proliferation but does not induce or prevent anergy. *J. Immunol.* **160**, 4175–4181
32. Smorodinsky-Atias, K., Goshen-Lago, T., Goldberg-Carp, A., Melamed, D., Shir, A., Mooshayef, N., Beenstock, J., Karamanah, Y., Darlyuk-Saadon, I., Livnah, O., Ahn, N. G., Admon, A., and Engelberg, D. (2016) Intrinsically active variants of Erk oncogenically transform cells and disclose unexpected autophosphorylation capability that is independent of TEY phosphorylation. *Mol. Biol. Cell.* **27**, 1026–1039
33. Wheelock, M. J., Shintani, Y., Maeda, M., Fukumoto, Y., and Johnson, K. R. (2008) Cadherin switching. *J. Cell Sci.* **121**, 727
34. Li, X., Wang, X., Tan, Z., Chen, S., and Guan, F. (2016) Role of glycans in cancer cells undergoing epithelial-mesenchymal transition. *Front. Oncol.* **6**, 33
35. Olea-Flores, M., Zuñiga-Eulogio, M. D., Mendoza-Catalán, M. A., Rodríguez-Ruiz, H. A., Castañeda-Saucedo, E., Ortuño-Pineda, C., Padilla-Benavides, T., and Navarro-Tito, N. (2019) Extracellular-signal regulated kinase: A central molecule driving epithelial-mesenchymal transition in cancer. *Int. J. Mol. Sci.* **20**, 2885
36. Lamouille, S., Xu, J., and Derynck, R. (2014) Molecular mechanisms of epithelial–mesenchymal transition. *Nat. Rev. Mol. Cell Biol.* **15**, 178–196
37. Shay, G., Lynch, C. C., and Fingleton, B. (2015) Moving targets: Emerging roles for MMPs in cancer progression and metastasis. *Matrix Biol.* **44–46**, 200–206
38. Arpino, V., Brock, M., and Gill, S. (2015) The role of TIMPs in regulation of extracellular matrix proteolysis. *Matrix Biol.* **44–46**, 247–254
39. Lommel, M., Winterhalter, P. R., Willer, T., Dahlhoff, M., Schneider, M. R., Bartels, M. F., Renner-Müller, I., Ruppert, T., Wolf, E., and Strahl, S. (2013) Protein O-mannosylation is crucial for E-cadherin–mediated cell adhesion. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 21024–21029
40. Carvalho, S., Oliveira, T., Bartels, M. F., Miyoshi, E., Pierce, M., Taniguchi, N., Carneiro, F., Seruca, R., Reis, C. A., Strahl, S., and Pinho, S. S. (2016) O-mannosylation and N-glycosylation: Two coordinated mechanisms regulating the tumour suppressor functions of E-cadherin in cancer. *Oncotarget* **7**, 65231–65246
41. Abbott, K. L., Troupe, K., Lee, I., and Pierce, M. (2006) Integrin-dependent neuroblastoma cell adhesion and migration on laminin is regulated by expression levels of two enzymes in the O-mannosyl-linked glycosylation pathway, PomGnT1 and GnT-Vb. *Exp. Cell Res.* **312**, 2837–2850
42. Khoder-Agha, F., Harrus, D., Brysbaert, G., Lensink, M. F., Harduin-Lepers, A., Glumoff, T., and Kellokumpu, S. (2019) Assembly of B4GALT1/ST6GAL1 heteromers in the Golgi membranes involves lateral interactions via highly charged surface domains. *J. Biol. Chem.* **294**, 14383–14393
43. Graham, J. B., Sunryd, J. C., Mathavan, K., Weir, E., Larsen, I. S. B., Halim, A., Clausen, H., Cousin, H., Alfandari, D., and Hebert, D. N. (2020) Endoplasmic reticulum transmembrane protein TMTC3 contributes to O-mannosylation of E-cadherin, cellular adherence, and embryonic gastrulation. *Mol. Biol. Cell* **31**, 167–183
44. Aclouque, H., Adams, M. S., Fishwick, K., Bronner-Fraser, M., and Nieto, M. A. (2009) Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. *J. Clin. Invest* **119**, 1438–1449
45. Thiery, J. P. (2002) Epithelial–mesenchymal transitions in tumour progression. *Nat. Rev. Cancer* **2**, 442–454
46. Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., Neilson, E. G., Sayegh, M. H., Izumo, S., and Kalluri, R. (2007) Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. *Nat. Med.* **13**, 952–961
47. Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shiptsin, M., Campbell, L. L., Polyak, K., Briskin, C., Yang, J., and Weinberg, R. A. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* **133**, 704–715
48. Haensel, D., and Dai, X. (2018) Epithelial-to-mesenchymal transition in cutaneous wound healing: Where we are and where we are heading. *Dev. Dyn.* **247**, 473–480
49. Nieto, M. A., Huang, R. Y., Jackson, R. A., and Thiery, J. P. (2016) EMT: 2016. *Cell* **166**, 21–45
50. Lou, Y., Preobrazhenska, O., auf dem Keller, U., Sutcliffe, M., Barclay, L., McDonald, P. C., Roskelley, C., Overall, C. M., and Dedhar, S. (2008) Epithelial-mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis. *Dev. Dyn.* **237**, 2755–2768
51. Schaeffer, D., Somarelli, J. A., Hanna, G., Palmer, G. M., and Garcia-Blanco, M. A. (2014) Cellular migration and invasion uncoupled: Increased migration is not an inexorable consequence of epithelial-to-mesenchymal transition. *Mol. Cell Biol.* **34**, 3486–3499
52. Ivaska, J. (2011) Vimentin : Central hub in EMT induction? *Small GTPases* **2**, 51–53
53. Van Hoof, J., and Harrison, F. (1986) Interaction between epithelial basement membrane and migrating mesoblast cells in the avian blastoderm. *Differentiation* **32**, 120–124
54. Nakaya, Y., Sukowati, E. W., Alev, C., Nakazawa, F., and Sheng, G. (2011) Involvement of dystroglycan in epithelial-mesenchymal transition during chick gastrulation. *Cells Tissues Organs* **193**, 64–73
55. LeBert, D. C., Squirrell, J. M., Rindy, J., Broadbridge, E., Lui, Y., Zakrzewska, A., Eliceiri, K. W., Meijer, A. H., and Huttenlocher, A. (2015) Matrix metalloproteinase 9 modulates collagen matrices and wound repair. *Development* **142**, 2136–2146
56. Bozzi, M., Sciandra, F., and Brancaccio, A. (2015) Role of gelatinases in pathological and physiological processes involving the dystrophin-glycoprotein complex. *Matrix Biol.* **44–46**, 130–137
57. Gui, T., Sun, Y., Shimokado, A., and Muragaki, Y. (2012) The roles of mitogen-activated protein kinase pathways in TGF- $\beta$ -induced epithelial-mesenchymal transition. *J. Signal. Transduct* **2012**, 289243
58. Huang, Q., Miller, M. R., Schappet, J., and Henry, M. D. (2015) The glycosyltransferase LARGE2 is repressed by Snail and ZEB1 in prostate cancer. *Cancer Biol. Ther.* **16**, 125–136
59. Day, B. W., Lathia, J. D., Bruce, Z. C., D'Souza, R. C. J., Baumgartner, U., Ensby, K. S., Lim, Y. C., Stringer, B. W., Akgül, S., Offenhäuser, C., Li, Y., Jamieson, P. R., Smith, F. M., Jurd, C. L. R., Robertson, T., *et al.* (2019) The dystroglycan receptor maintains glioma stem cells in the vascular niche. *Acta Neuropathol.* **138**, 1033–1052
60. Moreno-Layseca, P., and Streuli, C. H. (2014) Signalling pathways linking integrins with cell cycle progression. *Matrix Biol.* **34**, 144–153
61. Ferletta, M., Kikkawa, Y., Yu, H., Talts, J. F., Durbeek, M., Sonnenberg, A., Timpl, R., Campbell, K. P., Eklom, P., and Genersch, E. (2003) Opposing roles of integrin  $\alpha 6 \beta 1$  and dystroglycan in laminin-mediated extracellular signal-regulated kinase activation. *Mol. Biol. Cell* **14**, 2088–2103
62. Aikawa, R., Nagai, T., Kudoh, S., Zou, Y., Tanaka, M., Tamura, M., Akazawa, H., Takano, H., Nagai, R., and Komuro, I. (2002) Integrins play a critical role in mechanical stress-induced p38 MAPK activation. *Hypertension* **39**, 233–238

63. Doyle, E. L., Booher, N. J., Standage, D. S., Voytas, D. F., Brendel, V. P., Vandyk, J. K., and Bogdanove, A. J. (2012) TAL effector-Nucleotide targeter (TALE-NT) 2.0: Tools for TAL effector design and target prediction. *Nucleic Acids Res.* **40**, W117–W122
64. Cermak, T., Doyle, E. L., Christian, M., Wang, L., Zhang, Y., Schmidt, C., Baller, J. A., Somia, N. V., Bogdanove, A. J., and Voytas, D. F. (2011) Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. *Nucleic Acids Res.* **39**, e82
65. Michele, D. E., Barresi, R., Kanagawa, M., Saito, F., Cohn, R. D., Satz, J. S., Dollar, J., Nishino, I., Kelley, R. I., Somer, H., Straub, V., Mathews, K. D., Moore, S. A., and Campbell, K. P. (2002) Post-translational disruption of dystroglycan–ligand interactions in congenital muscular dystrophies. *Nature* **418**, 417–421
66. Kwon, M., and Firestein, B. L. (2013) DNA transfection: Calcium phosphate method. *Methods Mol. Biol.* **1018**, 107–110
67. Cox, J., and Mann, M. (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* **26**, 1367–1372
68. Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., and Mann, M. (2011) Andromeda: A peptide search engine integrated into the MaxQuant environment. *J. Proteome Res.* **10**, 1794–1805
69. Vizcaíno, J. A., Côté, R. G., Csordas, A., Dienes, J. A., Fabregat, A., Foster, J. M., Griss, J., Alpi, E., Birim, M., Contell, J., O’Kelly, G., Schoenegger, A., Ovelheiro, D., Pérez-Riverol, Y., Reisinger, F., *et al.* (2013) The PRoteomics IDentifications (PRIDE) database and associated tools: Status in 2013. *Nucleic Acids Res.* **41**, D1063–1069
70. Hoffmann, M., Pioch, M., Pralow, A., Hennig, R., Kottler, R., Reichl, U., and Rapp, E. (2018) The fine art of destruction: A guide to in-depth glycoproteomic analyses-exploiting the diagnostic potential of fragment ions. *Proteomics* **18**, e1800282
71. Pioch, M., Hoffmann, M., Pralow, A., Reichl, U., and Rapp, E. (2018) glyXtoolMS: An open-source pipeline for semiautomated analysis of glycopeptide mass spectrometry data. *Anal. Chem.* **90**, 11908–11916
72. Ruhaak, L. R., Hennig, R., Huhn, C., Borowiak, M., Dolhain, R. J., Deelder, A. M., Rapp, E., and Wuhrer, M. (2010) Optimized workflow for preparation of APTS-labeled *N*-glycans allowing high-throughput analysis of human plasma glycomes using 48-channel multiplexed CGE-LIF. *J. Proteome Res.* **9**, 6655–6664
73. Hennig, R., Cajic, S., Borowiak, M., Hoffmann, M., Kottler, R., Reichl, U., and Rapp, E. (2016) Towards personalized diagnostics via longitudinal study of the human plasma *N*-glycome. *Biochim. Biophys. Acta* **1860**, 1728–1738
74. Konze, S. A., Cajic, S., Oberbeck, A., Hennig, R., Pich, A., Rapp, E., and Buettner, F. F. R. (2017) Quantitative assessment of sialo-glycoproteins and *N*-glycans during cardiomyogenic differentiation of human induced pluripotent stem cells. *Chembiochem* **18**, 1317–1331
75. Thoeni, C., Waldherr, R., Scheuerer, J., Schmitteckert, S., Roeth, R., Niesler, B., Cutz, E., Flechtenmacher, C., Goepfert, B., Schirmacher, P., and Lasitschka, F. (2019) Expression analysis of ATP-binding cassette transporters ABCB11 and ABCB4 in primary sclerosing cholangitis and variety of pediatric and adult cholestatic and noncholestatic liver diseases. *Can. J. Gastroenterol. Hepatol.* **2019**, 1085717